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The thesis entitled "Quantitative Analysis of Certain Anatianginal Drugs in 
Pharmaceutical Formulations"\s comprised of five chapters. The first chapter describes 
a general literature survey of the subject matter. The very relevant matters include, a brief 
discussion on analytical chemistry, its relation with our daily life from the old age, role played in 
the field of pharmaceutical and biomedical analysis; various types of analytical techniques which 
are frequently used in the field under discussion; the validation of the developed method and 
the statistical treatments adopted during the data analysis to ensure and enforce the validity of 
the method. 
It is well known that the human nature is the most cautious in every era of the 
development. This lead to the birth of analytical chemistry as it deals with the study of the 
intrinsic properties of the materials to discover their valuable applicability or to warn the 
concerned one with the possibility of harm from them. Unlike other areas of studies in science, 
there are different properties, which heavily influence the results of the analytical methodology 
at each and every step; thus having direct impact on the results. These important properties 
have been discussed. With the passing time, the demands of the biochemical sciences and the 
advancement of the physical sciences opened the door of sophisticated instrumentation in the 
field of analytical chemistry. The different types of well-established analytical techniques have 
been discussed. 
Before or during the development of a method, it is necessary to be very careful of 
certain important things. These concepts have been discussed briefly. Once the analytical 
method is advent, it is necessary to decide its suitability for the intended purpose. This 
known as the method validation. Brief discussions of the validation, its components and the 
different international organisation involved in it, have been presented. When deciding for the 
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validation of the method, the role of statistical analysis can not be ignored. It is the only way to 
get the most conclusive results from the mathematical data obtained during the analysis. It also 
helps to decide with the progress of the work at each step. A detailed discussion of the 
statistical analysis has been given. 
As clear from the title of the thesis, it is based on the assay of certain specific 
pharmaceuticals i.e. antianginal drugs. A brief literature and classification of the concerned 
pharmaceuticals have also been presented. 
The second chapter describes the spectrophotometric method for the determination of 
nifedipine in drug formulations. The method depends on the reduction of nitro group to 
hydroxylamino group, which is then reacted with N-methyl-1,4-benzoquinoneimine to form 
coloured product [525 nm). The experimental conditions were optimised. Under the optimum 
experimental conditions Beer's law was obeyed over the concentration range of 5 - 175 fjg 
mf. The molar absorptivity, detection limit, recovery and RSD were found to be 1.9 xW^ L 
moh^ crrr^, 1.1 ijg mt', 99.7- 100.5% and 0.3 - 0.8%, respectively. The proposed method 
was compared favourably with the official B.P. method. 
The third chapter deals with a simple, rapid and economical spectrophotometric 
method for the assay of verapamil hydrochloride. Aqueous solution of verapamil is oxidised by 
the aqueous solution of chloramine-T in hydrochloric acid medium resulting in the formation of 
yellow coloured chromophore which absorbed maximally at 425 nm. The colour becomes 
constant within 13 minutes and remains so upto 20 minutes. The Beer's range was found to be 
0 - 340 fjg mt'. Rigorous statistical analysis of the calibration data was done to check and 
validate the strong correlation of the slope and intercept obtained for the regression equation. 
A plot of joint confidence by the method of Mandel and Linnig was drawn which results in an 
ellipse having its centre at the point of best fit. The obtained experimental data show excellent 
linearity (r - 0.9999). The application of this method on the dosage forms yields accurate and 
precise results. No interference from the commonly added adjuvants like carbohydrates was 
encountered as chloramine-T oxidises them only in the alkaline medium. This is a significant 
advantage. 
Two spectrophotometric methods for the assay of amiodipine besylate have been 
included in the fourth chapter. The first method is based on the charge transfer complexation 
reaction of amiodipine base molecule acting as the donor with that of the 2,3-dichloro 5,6-
dicyano 1,4-benzoquinone (DDQ) as acceptor in acetonitrile medium. Amiodipine base was 
previously obtained in bulk form in chloroform by the treatment of amiodipine besylate with 
aqueous sodium carbonate solution. The red coloured DDQ radical anion formed absorbed 
maximally at 435, JJ^'and 580 nm. In this method the determination was done at 580 nm. In 
the second method ascorbic acid was used as the reagent to develop a purple coloured 
complex [Xmax 530 nm) with the aliphatic -NH2 group of amiodipine molecule. In 1964, IBartos 
introduced ascorbic acid as a reagent for the detection and determination of aliphatic amino 
group. Since then the mechanism of the reaction has not been exactly elucidated. In this 
section the interest was also shown to propose the relevant reaction mechanism. For this 
purpose FTIR studies of the analyte and the reaction product were done. A tentative reaction 
mechanism has been given. The Beer's law was obeyed in the concentration range / - 125 
and W - MO ^jg mt' for DDQ and ascorbic acid methods, respectively. The molar 
absorptivity, slope, intercept and its confidence interval, correlation coefficient, linearity, 
standard analytical error, and confidence limit were calculated. The variances were found to be 
very low {4.44xlQ-e ^r^d 4.50x10-^hr DDQ and ascorbic acid methods, respectively). The 
'^"^ ' '^ >, THESIS 
results obtained by applying the proposea nfi^ods 6Ffhe locally available formulations were 
compared with that of the reference method using Student's /- and variance ratio F- tests. The 
joint confidence test was also applied to justify the existing relation of the slope and the 
intercept. 
In the last chapter of the thesis, the kinetic spectrophotometric determination of 
diltiazem hydrochloride has been included. To the best of our knowledge this is the first 
attempt to develop a kinetic spectrophotometric method for the determination of diltiazem 
hydrochloride in pharmaceutical formulations. The method is based on the oxidation of 
diltiazem hydrochloride by potassium permanganate in alkaline aqueous medium. A tentative 
reaction mechanism has been given. Four different methods of possible calibration curves have 
been proposed: The plots of (i) log intercept vs. log of molar concentration of diltiazem 
hydrochloride (log C); ( i i) log initial rate of formation of Mn04-2 vs. log C; {\\\) absorbance 
(610 nm) measured at a fixed time of 14 minutes vs. concentration; and (iv) log rate of 
degradation of potassium permanganate (530 nm) vs. log C, showed a linear dynamic range of 
1-7, 1-5, 1 - 7and 4 - 12fjg mL-', respectively. Different types of tests for the outliers in 
the data like Dixon's test and Grubb's test, test for normal distribution (David test) and test for 
the homoscedasticity of variances (Cochran test) were also performed. Detailed accuracy and 
precision studies have been done on both the pure as well as the dosage forms. Analysis of 
variance for the lack of fit test and for repeatability and intermediate precision were performed. 
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In the context of the present knowledge, the less predictive experiments, observations 
and interpretations of the ancient philosophers and scholars must be regarded as purely 
heuristic which were based on the superstitions and misunderstandings of the natural 
phenomena. Nevertheless, the account of those deeds of antiquity, the middle ages and even 
the first 350 years of the "modern age" make fascinating anecdotal reading. But even today 
it is a customary in good sense and justified too, to credit them who have, in fact, smoothen 
the pathway for the recent sophisticated and conclusive research works. 
It was Aristotle who had anticipated the nature of the hormones and claimed that the 
humours were secreted at certain cites to act elsewhere in the body and thus gave birth to the 
Chemical Science, and liberated it from the preconceived ideas of mysterious forces. During 
the period regarded as the "Quintessence to Chemical" (Paracelsus, 16"^  century-
Ehrlich, 19"^  century) [1], people had undergone major gradual change in the use of natural 
products in their entire states (mainly having medicinal importance) to either the purified 
extracts of the material of interest from those or to synthetic chemically-produced materials. 
Louis Pasteur (1822-1895) had given a great breakthrough to the 
chemotherapy for the treatment of infectious diseases caused by the pathogenic parasites. 
This lead to a wave in antiprotozoal chemotherapy system around 1890, which forced to 
develop some hypnotic, antimalarial and anti-inflammatory drugs, and adrenergic and 
cholinergic hormones, followed by the discovery of antibacterial and antibiotics, 
pharmacodynamics of analgesics, antihistaminics, vitamins and few new hormones. The post 
World War-ll period had given major breakthrough to the drug development and a number of 
antituberculous agents, the steroid hormones and contraceptives, antipsychotic, anxiolytic and 
antidepressant psycho-pharmacological drugs were discovered. And finally with the 
enforcement of Pure Food and Drug Act by the Food and Drug Administration of the 
United States, the therapeutic research, drug development, introduction and pharmaceutical 
manufacturing entered their "Golden Age" (1940-1960). 
With the cautious nature of human being and growing awareness especially for the 
health hazard reasons, the concept of quality emerged which lead to the interest in the work 
of analysis. With no name designated and no specificity given in the old age, analytical 
chemistry is the important part of the good quality life in every period of the development. 
The very basic aspect of analytical chemistry defines it as ''the relationship between the so-
called intrinsic chemical information of the objects and systems [2] and the information 
(results, reports) provided by the analytical systems (laboratories, on-site analysers etc)". A 
book written by Thomas De Quincey [3] can well document the old age relation of analytical 
chemistry with our daily life. In his book "Confessions of an English Opium Eater", the 
man of letters penned about his surgeon friend who was suffering from a lingering and fatal 
malady. The surgeon was on the horns of a dilemma as he had a family to support and thus 
eager to continue in work. Because of his professional knowledge, he saw the necessity of 
reducing his daily dose of opium that he took to alleviate his pains to a minimum. I now quote 
the words of De Quincey in this context: "But to do this he must first obtain the means of 
measuring the quantities of opium; not the "apparent quantities" as determined by 
weighing, but the "virtual quantities" after allowing for the alloy of varying amounts of 
impurities'. With the skills of the time (about 1820) De Quincey's surgeon friend was unable for 
such an evaluation. He did, however, achieve a uniform method of extracting the opium so as 
to give a fairly constant potency. G.D. Christian [4] has traced, in a report, the evolution of 
analytical chemistry into the 20* century and the revolution in quantitative analysis using 
modern analytical instruments. 
The chemical analysis is divided into qualitative and quantitative types of analyses. The 
qualitative analysis deals with the detection of constituents or components present in the 
analyte under investigation. The quantitative analysis determines the proportions in which the 
constituents or the amount of constituents are present in the matter of interest. 
Undoubtedly, as far as the quality in the analytical results is concerned, the top aim of 
the analytical chemists is to minimise the differences between the ideal, true information and 
that produced in the routine work. This primary goal of analytical chemist relies heavily on two 
capital analytical properties: the accuracy and the representativeness. In the search of 
excellency in these aspects, the analytical chemists worldwide are continuously making their 
best efforts for developing the sophisticated (accurate and precise) and sensitive techniques. 
Here the technical aspect is not including the instrumentation only, but also the various types 
of other trial like the suitable modifications in the methods of estimation, certain changes in the 
traditional ways of conducting the chemical reactions and sometimes developing new 
theoretical concepts for the old/previously existing instruments/methods. 
Not only the different theoretical aspects or the advance instrumentation (whether it is 
old or new) are affecting the quality in the analytical results but also it is seriously influenced by 
the different analytical properties. These analytical properties may be classified as the capital 
i^ccuraq and representativeness), basic (sensitivity, selectivity, precision and sampling) and 
accessory (expeditiousness, cost-effectiveness and personal-related considerations like 
personal safety and comfort). The capital analytical properties are associated with the 
consistency in tlie results and strongly rely on the basic properties which are responsible for 
the quality in the output of both inter as well as intra-laboratory analytical processes. Accessory 
analytical properties, though seems to be less significant, but often have major practical 
implications and sometimes affect the output heavily. Thus the basic and accessory properties 
are related to the analytical methodology. The hierarchy of these important components has 
been presented (Fig. 1.1) while their interdependence is shown in Fig. 1.2. 
Goals Quality Properties 
Results Representativeness ) Capital 
Obtaining more and 
better information 
Analytical process. 
Minimizing 
analysis time, 
expenses, labour 
& hazards 
Basic 
Accessory 
Figure 1 .1. Goals of analytical chemistry and their relationships to the analytical quality and 
analytical properties. 
Precision Cost-effectiveness 
Personal safety 
or comfoil 
Figure 1.2. Analytical tetrahedra showing interdependence of the analytical properties. 
An investigation of Fig. 1.1 shows that these are the basic properties, which are mainly 
deciding with the top goal of the analytical methodology, i.e. accuracy and representativeness. 
In fact these basic properties are themselves interdependent and affect each other strongly. 
Due to this strong relation, the excellency or even a simple enhancement in any of the basic 
property can only be achieved at the expense of another one. The present generic objective of 
the analytical chemistry is to get the high quality analytical information by expending minimum 
material, less time with least number of the man-power and minimum risks at the lowest cost of 
expense. 
As far as the pharmaceutical analysis is concerned, it always needs for the sensitive 
and sophisticated techniques. The most frequently used analytical techniques in pharmaceutical 
analysis are titrimetry, chromatography, electrochemical analysis and spectroscopy. Sometimes 
these techniques are combined with other supporting/subsidiary instruments like flow injection 
analysis system or kinetic type of analysis; thus making them more sensitive, selective and fast. 
In the field of drug analysis volumetric methods of analyses, either direct or indirect, 
have their own importance due to their inherent simplicity. This is the reason why still a large 
number of official methods for the determination of pharmaceuticals in the pharmacopoeias are 
based on titrimetry. Though it is the oldest technique in the market now but still having their 
recognition in the field of scientific research. 
Chromatographic methods have many applications in trace analysis and sometimes 
prove it as the only way. The different kind of it like paper chromatography, thin layer 
chromatography, column chromatography, capillary electrochromatography. high performance 
thin layer chromatography, high performance liquid chromatography and gas chromatography. 
have most frequent applications in the field of pharmaceutical as well as the biomedical 
analyses. Thin layer chromatography (TLC) is a simple, in-expensive and rapid technique, 
having wide applications for the separation and identification of impurities and degraded 
products [5]. Capillary electrochromatography (CEC) is a method in which liquid mobile phase 
is driven through a stationary phase in a packed capillary column by the electro-osmotic flow 
generated by a large difference in potential across the column [6-9] . CEC previously has been 
utilised for the separation of certain pharmaceuticals; an interesting example is that of a 
diastereoisomeric mixture not successfully separated on a chiral HPLC column [10], which 
clearly shows its considerable advantage. Among all the chromatographic methods, high 
performance liquid chromatography is most acceptable nowadays due to its sensitivity and 
selectivity even in a multicomponent mixture. It is widely used for the identification of drugs in 
plasma and dosage forms [11-24], and creating its own position in the dissolution 
monographs of pharmacopoeias for the assay of drugs in dissolution fluids [25, 26]. 
Electrochemical methods are characterised by high sensitivity, selectivity and accuracy. 
These methods are based on the basic electrical parameters like current (I), resistance (R) and 
voltage (V) which has been utilised alone or in combination for analytical purposes. 
Pharmaceuticals containing phenolic, amino, heterocyclic nitrogen, ketonic or aldehyde group 
undergo oxidation at their characteristic potentials and hence selectivity of the technique is 
increased. Important electrochemical techniques such as amperometry, conductometry, 
potentiometry, anodic and cathodic stripping voltammetry, differential pulse voltammetry and 
polarography have been used in drug analysis [27]. Ion-selective electrodes are 
electrochemical sensors that allow potentiometric measurements of the activity of particular 
species in aqueous and mixed solvents, or partial pressures of dissolved gases in water [28]. 
Potentiometric titrations are also reported in the pharmacopoeias as the standard method for 
the determination of certain drug substances [29-31], Despite the wide use of spectrometry 
and chromatography, analysts are choosing polarography and voltammetry due to their 
sensitive and characteristic qualitative as well as quantitative nature of analysis. Bersier has 
reviewed the importance of these techniques in pharmaceutical analysis [32]. 
Spectroscopic methods are widely used for the assay of drugs in pharmaceutical 
formulations. The most commonly used spectroscopic techniques for quantitative analysis are 
ultraviolet (UV) and visible methods. UV-spectrophotometry is best known and most widely 
applied in structure identification and quantitative analysis. It has become an established and 
fundamental technique in pharmaceutical research and analysis as well as in the broad area of 
organic and inorganic analysis. Conventional UV-spectrophotometric methods are simple, fast 
and economical and do not need any elaborate preparatory step for the samples prior to 
assay. Endriz [33] has described an UV-spectrophotometric method for the determination of 
heroin hydrochloride, methapyrilene hydrochloride, and quinine hydrochloride mixtures. The 
spectra for heroin, methapyrilene, and quinine show points of maximum absorption at 280 nm, 
313 nm and 348 nm, respectively. Methapyrilene and quinine do not seriously interfere with 
the heroin maximum, and methapyrilene in dilute acid solution absorbs only slightly at the 
quinine maximum of 348 nm. The procedure is fast and accurate enough for forensic purposes. 
Analyses of chloramphenicol and tetracycline hydrochloride [34] and phenobarbital and 
pentobarbital in pharmaceutical formulations [35] are further examples of the utility of UV-
spectrophotometry in this area. Because of the sensitivity of the UV method, the amount of 
sample required for the spectral identification is very small; drug levels and metabolites have 
been determined in biological tissues and fluids after separation and extraction. Since most 
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materials are not photosensitive, the technique is non-destructive, and the metabolite or drug 
can be recovered for further testing, However, these methods are inadequate in the presence 
of other components (like any drug of combination, excepients or decomposition products) 
showing similar UV spectra [36]. 
Photocolorimetric methods of analysis are performed in the visible region of light. They 
are based on the measurement of the absorbance of the coloured compounds. Usually, the 
analyte being colourless, they are reacted with the suitable chemical reagents in order to 
convert them in coloured compounds. Simple colorimetric and UV methods continue to be 
popular for carrying out single-component assays on a variety of formulated products. 
Representative examples of some of the many assays that have been published are given in 
Table 1.1. 
In the course of this discussion, the importance of computer-aided spectrophotometric 
determination of multicomponent systems can not be ignored. The quantitative 
spectrophotometric analysis of active ingredients in a solution containing more than two 
substances can be difficult to achieve by means of the traditional methods. In order to resolve 
this problem, several papers were published on the application of least squares method and 
orthogonal polynomials for the analysis of multicomponent systems [64-69]. 
Impurities present on the particle surfaces, e.g. from residual mother liquor, may be 
low in terms of percentage but they may change in a significant way the behaviour of the 
powder in the manufacturing process or in the final medicinal product. Therefore, a 
methodology is needed to detect such deficiencies at the surfaces or ia the upper layers of the 
powder. Spectroscopic reflectance tech.iq.e of sufficient sensitivity and precision could be of 
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help to discriminate between apparently identical materials from different sources or to detect 
inconsistencies between the batches from the same source. 
Near infrared (NIR) spectroscopy is a technique which has found its way into 
pharmaceutical control laboratories in recent years for raw material identification, water 
analysis and other pharmaceutical analyses [70-73]. Nuclear magnetic resonance (NMR) 
spectroscopy is a well-known spectroscopic technique specially used for the qualitative 
characterisation of the chemicals. In the recent attempts, NMR is also used as the sensitive 
quantitative method; a mini review has been presented in this context [74]. Moreover, NMR 
spectroscopy is favoured by chemists as a powerful technique for molecular structure 
determination. 
Chemiluminescence is a powerful tool for drug analysis since its detection limits are 
extremely low, its instrumentation is very simple and of low cost. In combination with the 
derivatisation techniques in order to increase sensitivity, it has a wide range of applications. 
The excellent sensitivity and the versatility of the chemiluminometric methods of analysis are 
the main reason for the recent surge of interest in chemiluminescence. Certain drugs have 
been analysed based on the phenomena of chemiluminescence in liquid phase [75-77]. 
Flow injection analysis (FIA) is characterised by its simplicity, speed and the use of in-
expensive equipment. In FIA, as a general principle [78], a quantity of accurately measured 
dissolved sample is injected or introduced into the carrier stream flowing through the system 
tubing, with or without additional changes like chemical reaction etc., occurring between the 
sample and the earner. As the analyte (or its react\or\ product) passes through the cont'muous 
detector, a transient signal is generated and recorded. Therefore, FIA has certain clear 
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advantages like (i) reduced reagent consumption [79]; (i i) high sampling frequency [80]; 
( i i i) safety in applying toxic reagents because the whole analysis proceeds in a closed system; 
and (iv) increased selectivity when the analyte is accompanied by more slowly reacting 
components. This technique has been utilised successfully in the determination of some 
compounds of pharmaceutical interest [27,81,82], In the recent years, atomic absorption and 
emission spectrophotometry is also frequently used in the field of pharniaceutkalanalysis [83-85]. 
Difference spectrophotometry is an important and useful technique used in the 
determination of medicinal substances by eliminating specific interference from the degradation 
products, co-formulated drugs and non-specific irrelevant absorption from the formulation 
matrix. The technique involves reproducible alterations of the spectral properties of the 
absorbance difference between two solutions, provided that the absorbance of the other 
absorbing substance is not affected by the reagent(s) used to alter the spectral property [86]. 
Derivative spectrophotometry is an analytical technique of great utility for both 
qualitative and quantitative information from spectra composed of unresolved bands. Although 
it was introduced more than thirty years ago [87-89] and has advantages for the solution of 
specific analytical problems. The derivative method has found applications not only in the UV-
visible spectrophotometry, but also in infrared [90], atomic absorption [91], flame emission 
spectrometry [92] and fluorimetry [93,94]. The use of derivative spectrometry is not restricted 
to special cases, but may be of advantage whenever quantitative study of normal spectra is 
difficult. Its disadvantage is that the differentiation degrades the signal-to-noise ratio, so that 
some form of smoothing is required in conjunction with the differentiation [95]. 
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Even though many pharmaceuticals show native fluorescence, there is also an 
important group of compounds, which is not fluorescent, can be determined by using 
fluorescent probes through derivatisation reactions. An account of the fluorescent probes more 
widely used for the determination of drugs and related compounds have been reviewed [96]. 
In the recent period, analysts are much interested in coupling the chromatographic 
techniques with that of the spectroscopic techniques. The advent of liquid chromatography with 
mass spectrometry, gas chromatography with tandem mass spectrometry and liquid 
chromatography-electrospray tandem mass spectrometry are good examples. Hirsch et a/. 
have determined the antibiotics using chromatography-electrospray tandem mass 
spectrometry[97]. Dielectric relaxation spectroscopy and x-ray powder diffractometry are also 
utilised for the identification of pharmaceuticals [98,99]. The safety of a drug product is 
dependent not only on the toxicological properties of the active drug substance itself, but also 
on the impurities that it contains. Monitoring of drug substance's impurities is routinely 
accomplished using HPLC. However, HPLC retention times can vary, resulting in uncertainty as 
to whether a peak at a new retention time is a new impurity. Because standards of the minor 
impurities (less than 0 .1% by area) are not usually available, some method is needed to 
characterise each of these peaks without isolating them. This on-line characterisation might be 
accomplished using UV diode array spectral matching [100], 
Whenever the question of mathematical and statistical treatments arises, the role of 
chemometrics can not be ignored. Chemometrics is defined as "the chemical discipline that 
uses mathematical, statistical and other methods of formal logic to design or select optimal 
procedures and experiments, and provide maximum chemical information by analysing chemical 
data" [101,102]. Chemometrics is the science that helps to make good use of information 
technology in the chemical analysis and to develop intelligent analysers, i.e. that automatically 
select the correct method for a given problem, carry it out, validate it and interpret the results. 
Kinetic method of analysis, which is in fact, the study of the measurement of 
concentration changes (detected via signal changes in a reactant, which may be the analyte 
itself) with time after the sample and reagents have been mixed, is developing since late 
1950s. They are not only the good choices for the drug analysis but very relevant to analytical 
chemistry in at least four respects: (a) it allows the elucidation of the physical, chemical and 
physico-chemical mechanisms on which analytical processes are based and hence their rational 
optimisation; (b) it facilitates the development of new analytical methods and techniques that 
are otherwise unattainable if the dynamic aspects are not dealt with; (c) it is the foundation of 
reaction rate methods (kinetic determinations); and (d) it contributes as sensitivity, selectivity 
and precision. The principles and applications of the kinetic methods have been reviewed 
[103-105]. Kinetic methods are generally rapid, reproducible and involve simple 
instrumentation. Though there are different modes of calibration in kinetic method, but the 
reaction rate methods involve two general aspects, which endow them with higher selectivity 
than equilibrium methods, namely the scarcity of parasitic blank signals and the possibility of 
using kinetic discrimination. In case of very fast reactions, the automatic handling is preferred 
for better and more accurate results; so the automation of the instrumentation is required. 
They can also be used to enhance the reproducibility and rapidity of slow reactions. Since 
kinetic methods of analysis require accurate timing, careful control over experimental 
conditions, precise sample and reagent preparation, proportioning and mixing, and accurate 
measurements of dynamic signals, hence they are well suited to intelligent automation. Kinetic 
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automatic techniques are generally based on open systems, among the most popular of which 
are stopped flow (SF) [106] system and the continuous addition of reagent (CAR) technique 
[107-110]. Several drugs have been determined by using the CAR technique with photometric 
[111,112] and fluorimetric detection [113], On the other hand, the CAR technique has been 
extended to chemiluminescence (CL) reactions as CAR chemiluminescence spectrometry 
(CARCL), a new approach, which have proved outstanding for the analysis of drugs and other 
substances of analytical interest. The use of catalysts to accelerate analytical reactions is 
feasible with both reaction rate and equilibrium determinations. In this concern, the use of 
micellar media in kinetic methods is recently encouraged to enhance the rate of reaction 
(through micellar catalysis) which in turn reduces the time of analysis and also improves the 
sensitivity and selectivity [114-117]. Multicomponent kinetic determinations, often called as 
differential rate methods, are also receiving a good deal of current attention in research 
laboratories. The various approaches to multicomponent determinations have been reviewed 
recently by Perez-Bendito [118]. One new approach that has been proposed for dealing with 
overlapping spectra is the kinetic wavelength-pair method [119], For a mixture of two 
components, the method relies on measuring the difference in the rate of change of 
absorbance with time at two pre-set wavelength pairs (four wavelengths). Another method 
called as the H-point standard addition method [120] proposed by Bosch-Reig et al. is 
capable of kinetic determination of components with overlapping spectra in their binary mixture. 
Pharmaceutical industry is one of the fast growing industries next to the information 
technology. Pharmaceutical analysis is a well-established section in the field of analytical 
chemistry whose advancements and works have been impressive in the last decades. 
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As mentioned above, the safety of drug products are dependent not only on the 
toxicological properties of the active drug substances itself but also on the impurities that it 
contains. Such impurities are associated with the drugs right from the manufacturing stages in 
the form of organic, inorganic and residual solvents (used to purify and generate the desired 
crystal morphology). The sources of such impurities may be the starting materials, intermediate 
and or synthetic by-products, reagents and catalysts. Furthermore, after getting the desired 
final product, the style of storage and class of packing may affect the stability of the drug 
substances, hence again leading to impurities, which raises a question mark on the 
recommended dosage amount supplied in the form of pharmaceutical formulations. Unlike 
other consumable products in the daily life, either the impurities or any abnormality in the 
recommended dosage amount of drug may lead to more adverse toxicological effects on the 
human life which may be life threatening. 
The requirements of quality, quantity, purity and safety of pharmaceutical formulations 
warrants a careful thought by every one associated with this area. Due to easy availability of 
sub-standard drugs and medicines in the markets of the developing countries, it is crucial to 
assay drugs in dosage forms. Hence development of rapid, simple and cost-effective analytical 
methods for the analysis of drugs are the need of the day in public defence. 
The increasing emphasis on the pharmacokinetic, bioavailability and therapeutic 
monitoring of drugs has placed a heavy burden on drug analysts. Reliable measurements of 
very low levels of drugs in complex matrices are frequently required. Because of the vast 
number of drugs introduced every year, more and more methods for drugs and metabolite 
determination are being developed either for routine or research use. Analytical procedures are 
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used throughout the drug development and the manufacturing of drug substances and drug 
products. Important decisions such as the establishment of the shelf-life from stability studies, 
the need for additional toxicological trials if new impurities appear or if known impurities exceed 
the qualified levels, the reworking of batches or batch release or rejection are based on 
analytical results. In order to make the right decisions and to avoid additional work, an 
appropriate performance of the analytical procedure is essential and this needs the 
"suitability of tiie metiiod for its intended use". 
Once an analytical method is advent, it is important to validate the method before it 
should be recommended for the routine analysis. Method validation of analytical procedure, i.e. 
the proof of its suitability for the intended purpose, is an important component in determining 
the reliability and reproducibility of the methods and is required for any regulatory submission. 
The method should be defensible with respect to regulatory requirements and reliable by 
incorporating statistical analysis to evaluate its performance. Validation of analytical methods 
has been the subject of discussion in recent years [121-124]. The procedure of validation 
requires the calculation and fitting of the experimental data within a standard fixed criteria. 
Statistical techniques are used to evaluate the linearity, precision, accuracy, 
robustness/ruggedness, sensitivity (limit of detection and quantitation) and specificity etc. 
Other aspects needing to be considered include identification and handling of samples prior to 
analysis, stability of samples under various storage conditions and the continuous assessment 
(quality control) of the method during its routine use. Before an analytical method is used for 
routine analysis it must be demonstrated first that the method fulfils certain performance 
criteria, when this has been documented, the method is said to be validated. 
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There are several international organisations and regulatory authorities, which are 
involved, in fixing the criteria for the validation. Some of them are listed below (Table 1.2). In 
the field of drug analysis, it is very clear that the definitions cover the entire field of analytical 
chemistry from bioanalysis to substance and product analysis. 
Table 1.2. Validation of analytical methods - international definitions. 
Organisation Applicability Remarks 
lUPAC Worldwide 
ILAC Worldwide 
WELAC Europe 
ICH Europe, Japan, USA Only pharmaceutical products. 
ISO Worldwide Lacks definitions of selectivity and specificity. 
Abbreviat ions: lUPAC, International Union of Pure and Applied Chemistry; ILAC, International Laboratory 
Accreditation Conference; WELAC, Western European Laboratory Accreditation Co-operation; ICH, International 
Conference On Harmonisation; ISO, International Organisation for Standardisation. 
It has been agreed that the key for evaluation of method reliability and overall 
performance are: (!) analyte stability, ( i i ) method selectivity/ specificity, ( i i i ) limit of detection 
and quantitation, ( i v ) accuracy and precision, ( v ) relationship between the response and 
concentration, ( v i ) recovery and ( v i i ) ruggedness. The overall validation strategy consists of 
four components, which are prevalidation, validation proper, study proper and statistical 
analysis. 
Prevalidation 
Prevalidation requires the availability of an authenticated analytical reference standard 
to prepare solutions of known concentrations. This standard should be of knom form, e.g. free 
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base or salt and of known purity, if used over a time, should be monitored to ensure no 
decomposition or contamination has taken place. Prevalidation provides the analyst an 
opportunity to obtain some practical experience with the method and helps to identify the 
optimum experimental conditions. It is also recommended that the following studies be 
conducted prior to initiating the validation proper. The appropriate measurements of 
concentration changes (detected via signal changes) in a reactant (which may be the analyte 
itself) with time after the sample and the reagents have been mixed. The optimum standard 
curve range and the number of calibrators should be established. The appropriate regression 
models which best fit the data is then selected. The extraction scheme and its recovery should 
be optimised to give insight into the limit of quantitation. 
Sampling and storage is an important initial part during the analytical studies. The 
quality of analytical data depends critically on the validity of the sample and the adequacy of 
the sampling procedure. Drugs may be lost to the container or be degraded chemically, 
photochemically or enzymetically during storage. Hence, an investigation of the stability of the 
drug during sample storage (temperature and duration) is a crucial part of the method 
validation. The lack of information on stability may jeopardise subsequent investigations. In 
general, the samples that will be analysed within a few days should be stored at 4 °C; those 
that are to be stored for longer should be kept at - 2 0 °C. For very long-term storage, freeze-
drying should be considered. Provided it is available in sufficient quantity, the sample should be 
divided into aliquots before freezing, to minimise precipitation or degradation due to repeated 
freezing and thawing. Stock solutions of photodegradable drugs should be stored in amber-
coloured containers. 
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Validation proper 
Among all of the international organisations, the ICH guidelines achieved a great deal 
in harmonising the definitions of the required validation characteristics and their basic 
requirements. The International Conference on the Harmonisation of the Technical 
Requirements for Registration of Pharmaceuticals for Human Use has harmonised the 
requirements in two guidelines [125,126]. The first one summarises and defines the validation 
characteristics needed for various types of test procedures; the second one extends the 
previous text to include the experimental data required and some statistical interpretation. 
These guidelines serve as a basis worldwide both for regulatory authorities and industry and 
bring the importance of a proper validation to the attention of all those involved in the process 
of submission. In order to fulfil the validation responsibilities properly, the background of the 
validation parameters and their consequences must be understood. Normally evaluated 
validation characteristics and their minimum number of determinations (if applicable) are listed 
in Table 1.3 [126]. 
There has been controversy regarding the technical term for the validation 
characteristic, i.e. specificity vs. selectivity, and the current definition of ICH is not clear in this 
respect. A clear distinction must be made between the terms "specific"diX\6 "selective". A 
specific reaction or test is one that occurs only with the substance of interest, while a selective 
reaction or test is one that can occur with other substances but exhibits a degree of preference 
for the substance of interest. Few reactions are specific, but many exhibit selectivity. WELAC 
refers the selectivity of a method to the extent to which it can determine particular analyte(s) in 
a complex mixture without interference from other components in the mixture. A method which 
21 
Table 1.3. Validation characteristics normally evaluated for the different types of procedures 
[125] and the minimum number of determinations required (if applicable) [126]. 
Validation 
Parameters 
Specificity'' 
Linearity 
Range 
Accuracy 
Precision 
Repeatability 
Intermediate 
Minimum number 
5 concentrations 
9 determinations over 3 
concentrations (e.g. 3x3) 
6 determinations at 100% or 9 
determinations over 3 concentration 
levels (e.g. 3x3). 
2 series 
Test procedure 
Identity 
Yes 
No 
No 
No 
No 
No 
Impurities 
Quantitative 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Limit 
Yes 
No 
No 
No 
No 
No 
Assay* 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Precision 
Reproducibility 
Detection 
limit 
Quantitation 
limit 
No 
No 
Nod 
Yes 
Yes No 
No No 
I^ncluding dissolution, content potency. 
*Lack of specificity of one analytical procedure could be compensated by other supporting analytical 
procedure(s). 
I^ntermediate precision sufficient for submission. 
'^ May be needed in some cases. 
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is perfectly selective for an analyte or a group of analytes is said to be specific. Tlius a specific 
test procedure measures quantitatively a chemical or a physical parameter of functional group 
of one or more different analytes in the sample matrix while a selective one detect qualitatively 
the analyte in the presence of components which may be expected to be present in the sample 
matrix. Fig, 1.3 gives a graphical presentation for the differentiation between selectivity and 
specificity. 
100%i, 
i^ 
•t to 
TO OJ 
^ 5> 
. 9 > CD 
CO 
(a) 
Non-Specific 
(A 
(D 
O 
O 
100%! 
d) 
^ § 
i : 03 
16 S. 
. ro TO 
cc 
I' (b) 
Not to be "Scaled" or graded Degree of selectivity (%) 100 
Fig. 1.3. Graphical demonstration of selectivity and specificity. The percentage of the 
measured signal attributable to the analyte alone (on the K-axis) is given as a 
function of the degree of selectivity (b) . A perfectly selective method is said to be 
specific (a). 
Calibration range is defined by the expected concentration in the samples, and will be 
usually in the linear range of the detector for that analyte, where the determined response is 
directly proportional to the concentration The calibration range should neither be too wide nor 
too narrow [122]. Least square linear regression is normally be used to define the calibration 
line mathematically. The range of an assay method can also be defined as the concentration 
intervals over which an analyte can be measured with acceptable precision and accuracy, 
wherease the linearity of an analytical procedure is its ability (within a given range) to obtain 
test results which are directly proportional to the conctmB!(^on (amount) of analyte in the 
sample [125]. It has been generally accepted that the coefficient of correlation of the line of 
regression should exceed 0.99 [127J. However, there are certain analytical procedures (TLC, 
IS 
fluorescence and atomic absorption spectrometry) with non-linear responses, which raises the 
question about the suitability of the calibration mode to be used in the procedure. The 
requirements and relevant parameters for the various calibrations are given in Table 1.4. 
Table 1.4. Requirements for the different calibration modes with relevant parameters. 
Quantitation Requirements Relevant parameters 
Single Point 
Calibration 
External standard 
Linear Function 
Non-significant 
ordinate intercept 
Homogeneity of 
variances^ 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
Inclusion of zero in confidence interval of the ordinate 
intercept, magnitude of the intercept (as percent of the 
signal at 100% test concentration). 
/^test of the variances at the lower and upper limits of 
the range. 
Multiple Point 
Calibration 
Linear, Unweighted 
Linear function 
Homogeneity of 
variances^ 
Linear, Weighted Linear function 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
F-\ts\ of the variances at the lower and upper limits of 
the range. 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
Non-linear Continuous function Appropriate equation 
100%-method For main peak: 
(area normalisation Linear function 
for impurities) 
Non-significant 
ordinate intercept 
Homogeneity of 
variances^ 
For impurities: 
Linear function 
May be presumed for a limited range (factor 10 - 20) 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
Inclusion of zero in confidence interval of the ordinate 
intercept, magnitude of the intercept (as percent of the 
signal at 100% test concentration). 
F-Xts\ of the variances at the lower and upper limits of 
the range. 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
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Bias is tlie difference between the expectation of the results and an accepted reference 
value. Bias is a systematic error (determinate error) contrast to the random error, There may 
be one or more systematic error components contributing to the bias. A larger systematic 
difference from the accepted reference value is reflected by larger bias value. Calibration 
curves are accepted for each individual batch during validation when no single standard has a 
% bias greater than 20% [122]. When a new analytical method is to be tested in a laboratory 
it may be used on samples of suitable reference material, but more often it is compared with an 
existing method on a range of suitable materials whose concentration levels are not known at 
all, precisely. It is important that the samples chosen cover the range of concentrations 
expected in future use, as the bias of the new method can vary with concentration. Regression 
techniques are commonly used to estimate the bias of the new method [128], 
Accuracy of an analytical procedure expresses the closeness of agreement between 
the value, which is accepted either as a conventional true value or an accepted reference value, 
and the value found [125]. The ICH guideline recommends the demonstration of accuracy over 
the whole working range. However, if only a narrow range is required (e.g. assay or impurities 
with a low specification limit), a six fold determination at a 100% test concentration may also 
be used, A quantitative approach to demonstrate the accuracy according to ICH guidelines have 
been given in Table 1.5. The analytical test to be validated is compared with another procedure 
or applied to a reference substance, the probably different specificities must be taken into 
account. Therefore, statistical tests should be performed only if the systematic bias based on 
these differences can be quantified and thus are corrected or are negligible. Otherwise the 
comparison should be performed as a qualitative verification of plausibility or an acceptable 
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maximum difference sliould be defined. Tiie accuracy can be established in different ways, 
using statistical analysis. 
Table 1.5. Quantitative approaches to demonstrate accuracy according to ICH [126]. 
Drug substance Application of the analytical procedure to a 
reference material. 
Comparison of the results with those of a 
second well characterised procedure. 
Drug product Application of the analytical procedure to 
synthetic mixtures of drug product components 
Spiking of analyte to drug product. 
Comparison of the results with those of a 
second well characterised procedure. 
Impurities (quantitative) Spiking of the impurity to drug substance or 
product. 
Comparison of the results with those of a 
second well characterised procedure. 
Precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed condition [125]. Precision should be measured 
using homogenous authentic samples. However, if it is not possible or if it is not practical to 
obtain a homogeneous sample, it may be measured using artificially prepared samples or 
sample solutions. Precision experiments study the effect of random variations on the 
performance of a method. Precision must be assessed in several ways: 
Repeatability, also termed as intra-assay precision, refers to the precision obtained 
under the same operating conditions over a short interval of time by applying the whole 
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analytical procedure to the sample. Repeatability should be assessed using a minimum of 6 
determinations at 100% of the test concentration or a minimum of 9 determinations over the 
range of the procedure (e.g. 3 replicates for each of 3 concentrations). This will provide an 
estimate of the random error of the method. 
Intermediate precision refers to within-laboratory variations, preferably performing a 
method over an extended period of time. The extent of investigation will depend on the 
intended use of the procedure. A typical investigation of intermediate precision would study 
various parameters that might include analysts, days, equipment, reagents, columns, etc. It is 
not required that each effect be studied individually so, therefore, experimental design is 
encouraged. 
Reproducibility is an estimate of the variation between different laboratories and is 
usually assessed by performing an inter-laboratory (collaborative) study. A study of 
reproducibility is not required as a part of the marketing authorisation dossier. 
Detection limit (DL) is the lowest amount of analyte that can be detected, as it (the 
analyte) yields Instrumental response greater than a blank, but can not be quantified. It is a 
parameter of "limit tesf'dinA expected to produce a response, which is significantly different 
from that of a blank. On the other hand, quantitation limit (QL) is a parameter of 
"determination test" and can be defined as the lowest concentration of analyte that can be 
measured and quantified with acceptable precision and accuracy. Hence, it is the lowest 
concentration included in the standard curve and is used to interpolate unknown sample 
concentration. One should be aware that the determined QL (or DL) is strongly related to the 
equipment actually used, as well as to the time of determination. They may represent more 
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system parameters than characteristics of the analytical procedure. In cases where a general 
QL is required, as in pharmaceutical analysis, it is essential to define a realistic QL (or DL) for 
the analytical procedure, independently from the equipment used, because this limit has 
important consequences (e.g. for the reporting threshold for impurities or for method transfer). 
DL and QL can be calculated from the standard deviation of the blanks. This approach 
is usually performed with instrumental methods. Measuring a blank sample, the standard 
deviation is calculated from the numerical outputs. DL and QL are defined as the 3.3 and 10 
fold, respectively, of the standard deviation of the blank. The values are converted to a 
concentration by the slope of a corresponding calibration line [126]. 
Robustness/ruggedness of an analytical method can be defined as "a measure of the 
capacity of analytical procedure to remain unaffected by small, but deliberate variations in 
method parameters and provides an indication of its reliability during normal usage " [ 129]. It 
can also be described as the ability to reproduce the (analytical) method in different 
laboratories or under different circumstances without the occurrence of unexpected differences 
in the obtained result(s), and a robustness test as an experimental set-up to evaluate the 
robustness of a method. Though these two terms have been frequently used as the synonyms 
[130] but sometimes a mutual differentiation have also been made [131], according to which 
the ruggedness is defined as the degree of reproducibility of the test results obtained under a 
variety of normal test conditions, such as different laboratories, different analysts, different 
instruments, different lots of reagents, different elapsed assay times, different assay 
temperature, different days, etc. The ICH guidelines also recommend that "one consequence 
of the evaluation of robustness should be that a series of system suitability parameters (e.g 
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resolution tests) is establisiied to ensure tiiat the validity of the analytical procedure is 
maintained whenever used" [M% Deliberate variations in the parameters of a procedure will 
provide an estimate of its reliability in routine use. The extent of robustness studies will depend 
upon the type of method but this evaluation should be considered during the development 
phase. Typical variations might include extraction time, flow rate through a testing device, 
stability of test solutions, etc. 
Study Proper and Statistical Analysis 
Daily standard curves are generated to determine the sample concentrations. The 
quality control sample sequence is carefully monitored for the systematic errors. For each 
standard curve, the slope, the intercept, variance and correlation coefficient should be 
reported. From the data generated, specific analytical parameters should be reported including 
linearity, accuracy, precision, sensitivity and recovery. Acceptance of the assay results is 
determined by monitoring the quality control results. If the concentrations are within the control 
chart's confidence limits established during the method validation, the data are considered 
valid. Upon completing a study proper and accepting the analytical runs, the quality control 
results are incorporated into their respective databases to update their confidence limits. 
Statistical calculations of the validation parameters and certain others of 
common interest 
Linear regression by least square method; Hoxmd}\s3^\on factor (unweighted linear regression: 
W= 1.4=1): ^ - ^ ( ^ . ) 
Means: 
X = ==^ y 
n « 
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Sum of squares: 
Residual sum of squares (Qyy) and Residual standard deviation (Sy): 
Qy.-
Q^ 
Q^ 
\Q^-
Q^' 
^y = 
Q xx 
n -2 
Slope (b), standard deviation of slope (Sb) and Relative confidence interval of the slope (CIt): 
, - ^ ' > H =' C^ = 
100=+i(P,« -2)*'ls^ [%] 
Intercept (a), standard deviation of intercept (Sa) and Confidence interval of the intercept (Cf 
upper and lower limits): 
( ^ =2 \ 
a = y -b^x s„ = Is,, * - + a -.ry 
1 X 
« Q XX 
CL^=a±t(P,n-2)*^' 
Standard error (5^ )^ and Relative standard error of slope (Ko) 
Coefficient of correlation (r): 
v^ =ioo*^[%] 
h ^ 
r = 
e ^ 
^ / a ^ yy 
Residuals and %-Difference: 
Where / , = experimental /-value and / {xj = calculated /-^alue for the given ;r-^alue. 
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Calculation of concentrations with uncertainties: 
Input of /-values: Calculation of concentration ^i\yo ~ — 7 — 
Input of A^values: Calculation of signal _y. = (3 + i * J:. 
Uncertainty and Relative uncertainty; 
+ 1-* J_ + _ + -:li—tJ— + 1-* — + — + z-L i 
h \n m b^ *Q^ i*^iOi) ^ « m b^ *Q^^ 
Accuracy 
(1) by comparison and validation procedure: 
Mean (;f), ^ " • * Z - . ^ J 
Confidence interval {CLfxJ upper and lower limit), 
Variance (5^, Standard deviation (s) and Coefficient of variation [CVox BSD), 
n - \ X 
Range[R%], ^ = ^^ ~_^^ * \ Q O 
Precision (Analysis of variance study): 
(1) Test for tfie homogeneity of variances according to Cochran. <j ^ 
i^ _ max 
Jt 
3-^ 
If > Cr(P, /7- I); variances are inhomogeneous. I<„,ax= 10,77^3^= 10 
Statistical linearity test 
As statistically based linearity test, the significance of the quadratic coefficient can be 
checked. If the confidence interval of the quadratic coefficient c {y = a + b*x + c*x2) 
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includes zero, the quadratic term becomes neglectable and the equation is reduced to a linear 
function (equations). 
Significance ofthe quadratic coefficient: CI^ = t{P,n - 3)'*^s^ 
CIc - confidence interval of the quadratic coefficient. 
If c± CIc includes 0, quadratic coefficient is not significant, and hence, no significant better fit 
by quadratic regression. 
The test according to Mandel is also based on a comparison of a linear and a 
quadratic response function. In this case, a test is performed to determine whether the 
quadratic function results in a significantly better fit by comparing the residual variances of 
both calibrations. If PG = 
(«-2)*4-(«-3)*4 
'y2 
> F(P, Fi - 1, F2 = n - 3); significant better fit by quadratic regression. Where s yi is 
residual variance linear regression and s y2 is residual variance linear regression. 
Linearity (overaii analysis, unweigiited linear regression) 
Comparison with the slope of the 1 st series: 
Limits of the equivalence interval: 
Ctr = 100J ib^ 
h 
exp [Sy t iP. >i+«, -4)]-ll C, =100 exp [-s,t[p,n,+n,-A)]-\\ 
5% = Acceptable difference (percentage). 
t(P,f) = Student's P- value for level of statistical confidence /'anddegreesoffreedom,/-/?,^/^-^ 
Where b,j, sbi,, n,j - slope, standard deviation of the slope, and number of values of series / 
and/ respectively. 
The slopes of series / and/are equivalent, H- d /^o < C , /N C < t^/o 
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Accuracy [recovery from linearity): Comparison of tlie slope with the theoretical value of /. 
Limits of the Equivalence interval: 
C^  =b-\-t{P,n-2) 
4Q^ 
C^=b-\ + t{P,n-2) 
M 
8 = acceptable difference (absolute value). 
tfP/j = Student's /*-value for level of statistical confidence /'and degrees of freedom, f-n-2. 
Sy,Qja= residual standard deviation, sum of squares. 
The slope is equivalent to the theoretical value of /, if - i f < C ^ / \ C^ i t? 
Accuraq[\^^\ recovery, comparison to reference): Comparison of the mean with a nominal value. 
Limits of the equivalence interval: 
T- nominal value (100% or reference value). 
6 = Acceptable difference (absolute value). 
t(P,f) ^ Student's /'-^alue for level of statistical confidence /'and degrees of freedom, f=n't 
Where 3f ,s,« = mean, standard deviation and number of values, respectively, 
/"areequivalent, if - SLCi ^C^ i. S 
Accuracy (Comparison to another procedure): Comparison of two means 
C_j = 10o| ^ exp[ -^( / ' ,« i+«2-2)s] - l l C^=100| - ^ exp fe^ i+«2 - 2 )5 ] -U 
s = \s ^  * 
n^ * X j 
+ . 
«2 * ^ 2 
2 _ («i - l ) * Sj + («2 ~ ^) *^2 
^f = 
n-^-^ n^ - 2 
6% = Acceptable difference (percentage). 
t(P,f) - Student's /-value for level of statistical confidence P and degrees of freedom, 
f=ni+n2- 2. 
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Where Jfi,2.^u^'^i2 =niean, variance, and number of values of series 1 and 2, respectively, 
The two means are equivalent, if - M iCj^^C^ < L9/O 
Precision (individualseries): Comparison of the standard deviation with a nominal value. 
Limits for the equivalence interval: 
s \ n-\ 
Cr =lOOi- ^ 7 r - 1 
« - l 
LCtr =100^ - , / ' ' r - 1 
6% = Acceptable difference (percentage of the standard deviation). 
y ( ^ . / ) = Chi-squared distribution for level of statistical confidence For f - P and 
degrees of freedom f- n-1. 
x,s^ ,n = mean, variance, and number of values. 
Experimental and target standard deviation are equivalent, if - i^/o iC^/sC^ < tWa 
Test for Outliers 
With regard to linearity, an outlier is characterised by a significant deviation from the 
regression curve. The 95% prediction interval can be used as a criterion [132]. This interval 
describes the range around the regression function in which a repeated analytical value can be 
expected in 19 out of 20 cases. If the calculation of the 95% prediction interval is performed 
with all values, a possible outlier might have a considerable influence on the calculation (by 
broadening the interval). The suspected value or values can be inactivated manually and a 
second regression is performed. If the deactivated value or values are now outside the 95% 
prediction interval, they can be suspected as being outliers. In the same manner, deviations 
from a linear response performing a linear regression can be detected. However, it must be 
taken into consideration that the prediction interval will be less stringent (broader) as the 
3 4 
extrapolation increases ("trumpet-shaped"). Most statistical tests and calculations are based 
on the assumption that the experimental values are only influenced by random variability (i.e. 
that they are normally distributed). Data that do not fulfil these assumptions (e.g. due to so 
called "gross errors", weighing, dilution, or by problems with the instrument etc.) will affect the 
results. It is the aim of outlier tests to identify such values in order to eliminate them before 
performing further calculations. However, the problem is especially with a small number of data 
where groupings could easily occur avoiding the incorrect rejection of values belonging to the 
same distribution. Therefore, outlier tests should be applied carefully and only obviously 
deviating values should be eliminated. When an outlier is identified, the absolute magnitude of 
the coefficient of variation (relative standard deviation) must also be considered for evaluation. 
If this parameter (calculated including the suspected "outlier") lies in a normally expected 
range, preferably all values should be retained. The question of systematic effects influencing 
the values (e.g. degradation or adsorption of the analyte, shifts in the equipment settings, etc.) 
is of more importance. This can be investigated by applying a trend test in which an unweighted 
linear regression is performed using the values in the order of the input (equidistant spacing 
with respect to the x dimension). The 95% confidence interval of the slope is then tested 
against the slope itself. If a slope can not be detected statistically, the hypothesis of a 
systematical trend can be rejected. 
Unweighted linear regression of / - / t o /7vs. x,. If Ck > abs(b)\\\er\ no trend. 
Where Ob = confidence interval of the slope tfP, n -2J= Student's /'-^alue for the level of 
statistical confidence /'and degrees of freedom n-2. 
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The outlier test according to Grubbs calculates the ratio of the difference between the 
largest/smallest value and the mean to the standard deviation. This parameter is then 
compared with the tabulated critical values. The test for double outliers searches for the 
occurrence of two outlying results. 
nmax - 50. Range of the values x,- from / to n. 
PG = -^-^ PG • = -^^ 
S S 
Test for single outliers: 
X = mean, 5 = standard deviation. 
An outlier may be suspected if PG\s larger than the tabulated value [133]. 
Test for double outliers: d^ =J>{Xj - x) 
2 - 1 
Test of the two smallest values: 
Test of the two smallest values 
An outlier may be suspected if PGls smaller than the tabulated value [133]. 
For the outlier test according to Dixon [134], differences between ordered values at 
the upper and lower extremes are divided by the whole range. This parameter is then 
compared with the critical tabulated values. 
nmax - 40. Range of the value xi, from / to n. 
PG = ^ ' PG - " "-^ 
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or 
¥oYn = 8-]2:<BR> 
or 
Vo^t n= 13-40:<BR> 
PG = ^ 3 - ^ 1 PG = ^" ^"-^ 
An outlier may be suspected if P(J\S larger than the tabulated value [135], 
Test for normal distribution (David's test) 
For all statistical tests used here, it is assumed that the experimental values are only 
influenced by random variability (i.e. that they are normally distributed). This can be checked 
with a statistical test according to David [136]. For this test, the ratio of the range (maximum 
to minimum value) to the standard deviation is compared with the tabulated critical limits. 
Relying on only a small number of data, the test for normal distribution is restricted to similar 
problems as discussed for the outlier tests. For a large number of analytical procedures, a 
normal distribution of the whole population can be generally assumed. The question of 
systematic effects influencing the values (e.g. degradation or adsorption of the analyte, shifts in 
the equipment settings, etc.), is of more importance. This can be investigated by applying a 
trend test. 
/?= range (maximum value - minimum value) 
s - standard deviation 
The values are (probably) normally distributed if Gu < R/s < Go 
Gu, 60.'lower and upper test limit. Tabulated value [136], 
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F- and htests: 
(i) Mean Mests: 
2 
f_test: If ^>F(P, J\J2) with s,^ > s '^^ 'then significant difference of variances 
exists. F(P, f1, f2) - Fisher's f-^alue for level of statistical confidence P and degrees of 
freedom // and 6-
If •^j p j ^^cc^^ayiitu . .p ,^  significant difference of mean exists. 
1^? If ^j" ^fempayiifx 
Where ^ ^ [('^ j " 0 * ^ / " ^ k^*?^^^^ " )^*^^ '^«?="^«1 ^; = ' ' ' j '^^iJM^ariJtfB 
' ' - / 
(ii) Nominal value Mest.' 
If —:^  * J«_, ) i (P, / ) significant difference to the reference exits. 
'3 
Where/=/7^-/and D^ = ^j ^r^erence 
t(P, f) - Student's /-value for level of statistical confidence /'and degrees of freedom f. 
and X, s,n = mean, standard deviation, number of values in validation series. 
CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic and 
inorganic compounds, They can be prepared synthetically (from chemicals) or can be directly 
obtained or reconstituted from the natural sources/products. All the drugs having medicinal 
importance can be broadly divided into two classes. 
Chemical classification: Here the drugs are classified according to their chemical 
structure and properties without taking the pharmacological actions under consideration. In this 
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class most of the drugs are having at least an organic substrate, the further classification is 
done in the relevant manner. 
Pharmacological classification: In this class the drugs are divided according to 
their action on the organism/organ (viz. heart, brain, lymphatic system, respiratory system, 
endocrine system, central nervous system etc.). Hence these drugs are named like antianginal, 
narcotics, soporifics, analgesics, diuretics and anaesthetics etc. Further classification of each 
group is done according to the therapeutic/pharmacological specificity with the relevant organ. 
A detailed classification of drugs with respect to their therapeutic importance for the 
cardiovascular system has been given in Table 1.6 [137]. 
ANTIANGINALS 
Angina pectoris is a heart ailment characterised by pressing chest pain that often 
radiates to the neck area and arms and shoulders (often towards left side). As a clinical entity 
it was first characterised under the name Pectoris Do/orhy William Heberden in 1768, although 
its symptoms had been noted as early as 1632 [138-140]. In the recent medical terminology 
it is referred as the symptom of ischaemic heart disease. For nearly a century following its first 
description, there was not much that could be done to relieve an angina patient of his agony; 
brandy, ether, chloroform, ammonia and other stimulants and depressants had been tried, but 
nothing seem to bring comfort. The breakthrough came in 1867 when T. Lauder Brunton, a 
British physician, reported his success with amy! nitrite. In the authoritative but lively journal of 
medicine, the Lancet, he wrote, " On pouring from five to ten drops of (amyl) nitrite on a ciotii 
and giving it to tt^e patient to intiale, the pain completely disappeared and, generally did 
not return till its wonted time next nigiit"[\A^. And finally the continuous effort of the medical 
39 
<u 
o 
> o 
03 
E 
T 3 
*+— 
O 
' i75 
1/1 JO 
^ 
E 
^ 
I 
I 
"en 
s 
•5; 
•5 « 
•e D) 
E 5 2X3 
- 0) 
i2tg 
S 9-
ro 3 
0 0 
TO 
2 
"5 
c 
¥ 
^ 75 05 
I 
! 
I 
E 
t 
5 
e I 
(5 
5 
• o 
o 
•s 
5 
Q-
I 0) 
ro 
I I 
o 
T3 
ro 
E 
E 
D 
c 
E 
3 
I I 
5 I ^ 
(D c(= 
</) — 
^ c 
0) C3) 0) E 0) (?-§ ^^ W^ 
a ro o >, o ffi 
n>>- e ' l p-q 
^1 s | . ES 
TO O TO 0 TO 
(2 
0) 
^ 
1 I 
3 I 
— c 
O O) 
o 
0 
M-0 
researchers, they got succeeded in knowing the different reasons with this life-threatening 
ailment and its therapeutic solutions. 
Drugs used in angina pectoris are those that reduce cardiac work and myocardial need 
by (a) unloading the heart, (b) dilating capacitance and resistance vessels, (c) dilating 
coronary arteries and (d) blocking l i - adrenoceptors. Anginal pain occurs when the coronary 
blood flow is insufficient to meet the heart's metabolic requirements. The drugs that either 
improve myocardial perfusion or reduce the metabolic demand, or both can counteract it. 
Several antianginal drugs are available for the treatment of angina. These include (a) organic 
nitrates, (b) beta-adrenergic blockers, (c) calcium channel blockers, (d) potassium channel 
activators, (e) antiplatelet drugs and (f) certain others like diazepam, oxyfedrine etc. 
This thesis deals with the quantitative analysis of certain antianginal drugs namely, 
nifedipine, verapamil hydrochloride, amiodipine besylate and diltiazem hydrochloride in 
pharmaceutical formulations. 
Nifedipine (C17H18N2O6) 
Nifedipine is chemically dimethyl-1,4-dihydro-2,6-dimethyl-4-(2-nltrophenyl) 
pyridine-3,5-dicarboxylate promising for the following structure (Structure I). It is referred as 
the prototype compound of dihydropyridine class of calcium channel blockers having properties 
of peripheral and coronary vasodilation. It is orally administered for the management of 
hypertension and angina pectoris and functions primarily through its vasodilating properties as 
an afterload reducer. 
Since nifedipine is extremely sensitive to photo-oxidation, manufacturers take great 
care in the storage and packaging of nifedipine to protect it from photodegradation due to 
n 
H,C 
H3COOC 
Structure I 
inadvertent light exposure and thus to maintain its therapeutic potency, But due to the same 
reason, official United States Pharmacopoeia recommend that the measured amount of 
nifedipine in commercial preparations may vary in the range 90—110% of the labelled quantity. 
Verapamil hydrochloride (C27H38N2O4. HCI) 
Verapamil hydrochloride, chemically designated as 5-[N-(3,4-dimethoxyphenylethyl) 
methylamino]—2-(3,4—dimethoxyphenyl)—2—isopropyl valeronitrile monohydrochloride is an 
antiarrhythmic as well as a calcium channel blocker belonging to the phenylalkylamine class of 
compound. The following structure (Structure II) has been suggested for verapamil 
hydrochloride. 
H3CO 
H3C0 
CH(CH3)2 CH, 
CH2CH2NCH2CH2CH2C CN • HCI 
OCHo 
Structure OCH, 
Verapamil is administered orally as the racemic mixture and well absorbed rapidly. 
Verapamil is metabolised stereoselectively, the more active enantiomer being more rapidly 
metabolised. According to pliarmacopoeial definitions, it contains not less than 99.0% and not 
more than 101.0% of C27H38N2O4. HCI, calculated with respect to the dried substance. 
Amiodipine besylate (C20H25CIN2O5. CeHeOsS) 
Amiodipine besylate is comparatively a new calcium channel blocker, and is chemically 
defined as 3-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-
6-methyl pyridine-3,5-dicarboxylate monobenzene sulphonate (Structure III). 
H 
HaC. N. .CH2OCH2CH2NH2 
H3COOC 
CL H 
Structure III 
It also belongs to dihydropyridine group of calcium channel blockers, undergoing 
photodegradation and showing almost similar therapeutic behaviour, 
Dlltiazem hydrochloride (C22H26N2O4S. HCI) 
Diltlazem hydrochloride has been defined in the pharmacopoeias as (+) —5 - [ 2 — 
(dimethylamino)ethyl] - cis - 2 , 3 - dihydro - 3 - hydroxy - 2 - (p - methoxyphenyl) -
1,5 - benzothiazepin - 4 (5H) - one acetate, containing not less than 98.5% and not more 
than 101.5% of Q^H^eNAS. HCI (Structure IV), calculated on the dried basis. 
H3C0 
structure IV 
43 
Diltiazem bears the peripheral and coronary vasodilation therapeutic properties. It 
lowers blood pressure and has some effect on cardiac conduction, it is orally administered for 
the management of angina pectoris and hypertension, and may also be given intravenously in 
the treatment of atrial fibrillation or flutter and paroxysmal supraventricular tachycardia. 
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Introduction 
Nifedipine, chemically dimethyl-1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl) 
pyridine-3,5-dicarboxylate and pharmacologically a selective L-type slow calcium channel 
antagonist [1-2 ] , is official in United States Pharmacopoeia XXIII and British Pharmacopoeia 
[3-4 ] . It is commonly used as an antihypertensive and potent arterial vasodilator in the 
management of angina and various other cardiovascular disorders [5]. It is also used as a 
probe drug to assess cytochrome P-450 III A4 enzyme activity in vivo [6]. Nifedipine 
decreases cyclic guanosine monophosphate in hypoxic lungs like inhaled nitric oxide, exhibits 
dose dependent depressive effect and causes some common side effects due to excessive 
vasodilation [7-9] . 
Several HPLC [6,10-12], reversed phase HPLC [13-14], HPTLC [15], GC [12,16-
19] and voltammetric [20] methods have been reported for the assay of nifedipine and its 
related compounds in pharmaceuticals. A variety of HPLC and GC methods are now widely used 
for the determination of nifedipine concentration in biological fluids because of their sensitivity 
and specificity. These methods have adequate sensitivity to assay lower concentrations of the 
drug and hence use of these methods is justified when the sample matrix is complex and 
nifedipine concentration is low as in the case with the biological samples. However, the sample 
matrix is usually less complex and analyte concentration levels are high in case of 
pharmaceuticals, hence it is required to develop fast, simple and inexpensive method that can 
be adopted for routine analysis. Therefore, spectrophotometry is still considered as a 
convenient and low cost technique. 
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Nifedipine was assayed [21 ] in pharmaceutical formulations based on the reaction with 
4-dimethylaminobenzaldehyde and subsequent determination at 310 nm. Beer-Lambert's law 
was obeyed over the concentration range 5 - 60 |ig m b ^ Another spectrophotometric 
method has also been recommended for its determination involving the formation of blue 
complex with Folin-Ciocalteau reagent [22]. A kinetic spectrophotometric method was 
described for its determination in dosage forms, The method was based on its oxidation by 
potassium permanganate at neutral pH [23], In commercial dosage forms, UV-
spectrophotometry has also been utilised for its estimation [24-25]. Nifedipine has also been 
determined using 3,4,5^rimethoxybenzaldehyde [26]. The Beer's law was obeyed over the 
concentration range 10 - 70 pg mL-^ with RSD of 1.5%. The quantification of nifedipine in 
combined dosage forms were made using first derivative [12] and second derivative [27] 
spectra of their solutions in methanol and 0.1 N HCI, respectively. 
This chapter describes a new method for the determination of nifedipine in commercial 
dosage forms. The method depends on the reduction of nitro group to hydroxylamino group, 
which then reacted with N-methyl-1,4-benzoquinoneimine to form coloured product. The 
reduction of nitro group of nifedipine to hydroxylamino derivative was studied with respect to 
heating time and concentration of Zn / NH4CI. The effects of reagent's concentration, buffer and 
time on the formation of chromophore were investigated. 
Experimental 
Apparatus 
Spectral runs and absorbances were recorded on a Spectronic 20D+ 
spectrophotometer (Milton Roy, USA). pH-^neter model L1-10T (Elico, India) was used to 
measure the pH. 
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Materials and Reagents 
(i) 0 .1% ethanolic solution of reduced nifedipine was prepared by heating a mixture of 
100 mg pure nifedipine (J.B. Ciiemicais and Pliarmaceuticals Ltd., India) dissolved in 20 mL 
ethanol, 15 mL of 10% aqueous solution of ammonium chloride (Loba Chemie, India) and 2 g 
of zinc dust for 8 minutes on a water-bath at 100±1 °C, The content was cooled at room 
temperature and diluted by adding 30 mL of ethanol. It was filtered on whatmann no. 42 filter 
paper and washed with ethanol. The filtrate and washings were diluted to volume in a 100 mL 
volumetric flask. The whole experiment was performed in dark and in amber coloured 
glasswares. This solution was stable at room temperature for about 4 days. 
( i i) A buffer solution was prepared by mixing appropriate volumes of 1 M hydrochloric 
acid (E. Merck, India) and 1 M sodium acetate trihydrate (Ranbaxy Chemicals, India). 
( i i i ) 0.2% aqueous solution of 4-(methylamino)phenol (Loba Chemie) was prepared 
in doubly distilled water. It was always freshly prepared after every five hours. 
(iv) 0.01 M potassium dichromate (Loba Chemie) was prepared by dissolving 0.7355 
g in doubly distilled water and made up to 250 mL. 
Recommended Procedure 
Aliquots of 0.05 -1.75 mL of reduced nifedipine (1 mg mL"^) were transferred into a 
series of 10 mL standard volumetric flasks and then 2.5 mL of buffer solution (pH = 2.9), 1.45 
mL of 0.2% 4-(methylamino) phenol and 1.2 mL of 0.01 M potassium dichromate were added 
to each flask successively. The solutions were allowed to stand at room temperature for 18 
minutes and then made upto the mark with doubly distilled water. The absorbance values of the 
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final coloured solutions were measured at BZBtirr^iaJr^t^^^^^genfblank. The amount of the 
drug was computed from a Beer-Lambert's plot. 
Analysis of pharmaceutical formulations 
10 tablets of nifedipine (each claiming 10 mg) were finely powdered and thoroughly 
mixed. The powdered mixture was transferred in a conical flask. 20 mL of ethanol was added 
and gently shaken for 2 - 3 minutes. Then 15 mL of 10% ammonium chloride solution and 2 g 
of zinc dust were added and heated on a water bath for 8 minutes. After cooling at room 
temperature, the mixture was added with 30 mL of ethanol and filtered on whatmann filter 
paper no. 42 in a 100 mL standard volumetric flask. The residue was washed with enough 
ethanol and finally made upto the mark. Nifedipine content was determined using the 
recommended procedure. 
Investigation of stability 
The stability of nifedipine under the experimental conditions was investigated by 
incubating 120 |ig mL"^  in distilled water or ethanol containing common excipients at 30 °C for 
3 hours in the absence of all lights. At regular time interval the concentration of nifedipine was 
determined by the proposed and reference methods [23]. 
Results and discussion 
The nitro compounds undergo reduction by catalytic hydrogenation in the presence of 
metals (Zn, Fe, Sn) and other suitable reagents like, HCI, NH4CI, NaOH or KOH. Under 
the proposed condition, nifedipine is reduced to hydroxyiamino derivative by Zn / NH4CI. 
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The primary aromatic amines react with 4-(methylamino)phenol and an oxidising 
agent such as dichromate [28], N-bromosuccinimide [29], peroxydisulphate [30] or 
iodylbenzoate [31] to form a purple red product. It is believed that on oxidation 4 -
(methylamino)phenol produces N-methyl-1,4-benzoquinoneimine. The primary aromatic 
amines react with N-methyl-1,4-benzoquinoneimine to form chromophore, which absorbed 
maximally at 520 - 530 nm. In this study the reaction of hydroxylamino derivative of nifedipine 
with 4-(methylamino)phenol and potassium dichromate may be assumed to proceed in an 
analogous manner as the product absorbed maximally at 525 nm (Fig. 2.1) [28]. The 
stoichiometric ratio of hydroxylamino derivative to N-methyl-1,4-benzoquinoneimine was 
determined by Job's method [32] and was found to be 2 : 1 (Fig. 2.2). The chromophore 
formed was found to be positively charged at pH 2.9 as it was adsorbed on cation-exchange 
resin beads. The possible reaction sequence is presented in Scheme 2,1. 
The optimum conditions for the reduction of nifedipine to hydroxylamino derivative 
were established via a number of preliminary experiments. The effect of variables on the 
reduction of the drug was studied by taking a separate 10 mL aliquots of 0 .1% nifedipine 
solution. 
Effect of heating time 
The aliquot of nifedipine was mixed with 200 mg of zinc dust and 1.5 mL of 10% 
ammonium chloride solution and the content was heated on a water bath at 10011 °C. One mL 
aliquot of this solution was subjected to colour dadopment The results showed that the intensity 
of the colour was reached to its maximum at 7 minutes of heating (Fig. 2.3) and remained 
unchanged even after 10 minutes. Therelbre,aheatingtimeof8rinuteswasrecommended for reduction. 
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(a)Reduction of nifedipine to hvdroxylamino derivative 
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Effect of Zinc dust 
The effect of the amount of zinc dust on the reduction of 10 mg nifedipine in the 
presence of 1.5 mL of 10% ammonium chloride solution was studied. It was observed that the 
absorbance of the coloured solution increased upto 150 mg of zinc dust and then remained 
constant at higher amounts (Fig. 2,4). Hence, 200 mg of zinc dust was taken as optimum 
value for reduction. 
Effect of ammonium ciiloride solution 
To study the effect of the concentration of ammonium chloride solution on the 
reduction of nifedipine, 10 mL of 0 .1% nifedipine was mixed with 200 mg of zinc dust and 
varying volumes of 10% ammonium chloride solution. The content was heated on a water bath 
at 100+1 °C for 8 minutes. A plot of absorbance vs. volume of ammonium chloride solution 
showed that the highest absorbance was obtained with 1.25 mL and remained constant 
beyond this volume (Fig. 2.5). Therefore, 1.5 mL of 10% ammonium chloride solution was 
taken to reduce the drug for further studies. 
The optimum conditions for the development of the proposed method were established 
by varying the parameters one at a time and observing the effects produced. 
Effect of buffer solution 
Fig. 2.6 shows the effect of HCI-CHsCOONa buffer on the formation of chromophore. 
A constant absorbance was observed in the pH range of 2.75 - 3.1. In this study, therefore, 
2.5 mL of pH 2.9 buffer solution was used throughout the experimental investigations. 
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Effect of time 
To 1 mL of 0.1% reduced drug, 2.5 mL of buffer solution (pH = 2.9), 1.45 mL of 
0.2% 4-(methylamino)phenol solution and 1.2 mL of 0.01 M potassium dichromate were 
added and kept at room temperature (25 °C) for colour development. The coloured product 
was diluted to 10 mL with distilled water and the absorbance was measured at 525 nm against 
a reagent blank after 18 minutes. The intensity of the colour was reached to maximum after 15 
minutes (Fig. 2.7) and remained constant for one hour. 
Effect of 4-(methylamino)phenol solution 
1 ml of 0.1% reduced drug, was mixed with 2.5 mL of buffer solution (pH = 2.9), 
varying volumes of 0.2% 4-(methylamino)phenol and 1.2 mL of 0.01 M potassium dichromate 
and the contents were allowed to stand at room temperature for 18 minutes. The results 
showed that a constant absorbance was found in the range of 1.4 - 1.5 mL (Fig. 2.8). 
Therefore 1.45 mL of 0.2% 4-(methylamino)phenol was used in all the subsequent works. 
Effect of potassium dichromate solution 
In order to study the effect of potassium dichromate concentration, the reaction was 
carried out in a series of 10 mL volumetric flasks containing 100 jug mL-^  reduced drug, 2.5 
mL of buffer solution (pH = 2.9), 1.45 mL of 0.2% 4-(methylamino)phenol solution. This was 
followed by different volumes of 0.01 M potassium dichromate ranging from 0.3 to 1.5 mL. The 
results (Fig. 2.9) indicate that the highest intensity and reproducible results are obtained on 
using 1 mL of 0.01 M potassium dichromate. Therefore, 1.2 mL of this reagent was used 
throughout this work. 
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Analytical data 
Under the optimum experimental conditions, a calibration curve was constructed by 
plotting absorbance at 525 nm versus concentration (Fig. 2.10). Beer's law was obeyed within 
a concentration range of 5 - 175 |j.g mL~^ Regression analysis using the method of least 
square was made to evaluate the slope, intercept and correlation coefficient. The linear 
regression equation and correlation coefficient are A = 1.3 x 10 -^ + 5.3 x 10 -^ C [A, 
absorbance at 525 nm; Q concentration in |ig mL-^) and r = 0.9999 which indicates an 
excellent linearity. The molar absorptivity, detection limit and variance [33], standard 
deviations of intercept and slope [34] were found to be 1.9 x 1 0 H moM m-\ 1.1 |ig mL-' 
and 1.2 X 10-^ 1.9 X 10"^ and 1.6 x 10"^ respectively. The small value of variance marks the 
negligible scattering of the experimental data points from the line of regression. 
The error, Sa in the determination of a given concentration of nifedipine was calculated 
by statistical analysis of the calibration data using the relation [35]. 
where Cand A'= average concentration and average absorbance values, respectively, for n 
standard solutions. Fig. 2.11 shows the graph of 5^ against the concentration of nifedipine. The 
value of Sc reached to minimum when the actual absorbance was equal to the average 
absorbance in the calibration graph. Thus the minimum error was found in the determination of 
about 100 ^g mL-^ nifedipine. The value of 5, also allows to establish the confidence limits at 
the selected level of significance [35]. The results are shown in the Fig 2.12 in the form of 
percent uncertainty on the concentration at 95% confidence level. It is apparent from the figure 
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that the relative uncertainty on the concentration can be calculated directly over the full range 
of the concentration tested and hence, confidence limit can be established. 
The stability experiment conducted in the presence of commonly encountered 
excipients such as starch, talc, lactose and magnesium stearate revealed the fact that under 
the conditions, no degradation of nifedipine was detected. The drug and its photodegradation 
product, 4-(2-nitrosophenyl)-pyridine homologue may undergo reduction with Zn/ NH4G to 
yield hydroxylamino derivative. However, the determination was done under a condition where 
contact with light was completely avoided. 
The reproducibility of the method was checked by ten replicate determinations at the 
concentration levels of 60, 100, 120 and 150 ^g mL-^. The percent relative standard 
dev\aV\ons were found \o N/av^  between O.S - 0.8. 
The accuracy of the method was demonstrated by recovery experiments, which were 
carried out by adding a fixed amount of pure drug to the preanalysed formulations. The 
analytical results obtained from these investigations are summarised in Table 2.1, which 
indicates that the common additives and excipients did not interfere with the determination. The 
percent relative standard deviations can be considered to be very satisfactory. 
The proposed method was compared favourably with other existing UV-visible 
spectrophotometric methods (Table 22). It is evident from the table that the method has 
advantages of wider linear dynamic range and high precision (%RSD = 0.3 - 0.8 and 0.4 -
0.7 for pure and dosage forms, respectively). Some commercial dosage forms were 
successfully analysed by the proposed method and official B.P. method [4]. The results (Table 
2.3) were compared statistically byStudent's Mest and variance ratio /^est , which indicates 
that there is no significant difference between the methods compared. 
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Table 2 . 1 . Spectrophotometric determination of nifedipine in pharmaceutical formulations 
by standard addition method. 
Preparations 
AdalatRetard-10 
Calcigard—10 
NicardiaRetard-10 
Taken 
30 
40 
80 
30 
40 
80 
30 
40 
80 
Amount (pg mL-
added 
30 
60 
40 
30 
60 
40 
30 
60 
40 
') 
found 
60.1 
99.5 
120.4 
59.5 
99.8 
120.7 
59.5 
100.4 
120.5 
Recovery 
(%) 
100.1 
99.5 
100.3 
99.2 
99.8 
100.6 
99.2 
100.4 
100.4 
RSD 
(%) 
0.8 
0.6 
0.5 
1.0 
0.8 
0.5 
0.7 
0.4 
0.5 
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Table 2.2. Comparison of the proposed method with the existing spectrophotometric 
methods for the assay of nifedipine in pharmaceutical formulations. 
Reagents y^^^^ Linear Dynamic Recovery RSD References 
(nm) Range (^ ig mL-i) (%) (%) 
Potassium permanganate 530 18-44 99.5-101.3 1.5 [23] 
3,4,5-trimethoxybenzaldehyde 365 10-70 100.2- 1.5 [26] 
102,9 
4 i^methylaminobezaldehyde 310 5-60 97.8-98.5 - [21] 
* Extractive U.V. 
Ethanol and phosphate buffer 
saline 
Derivative U.V. 
4-N-methylaminophenol 
and dichromate 
237 
340 
400 
525 
0 -10 
-
4 -12 
5-175 
97.8-98.9 
99.7-99.9 
98.5-101.3 
99.7-100.5 
— 
-
1.4 
0.6 
[25] 
[24] 
[12] 
This work 
Extracted into chloroform and the solvent was evaporated to dryness. Finally, the residue was 
dissolved in distilled water. 
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Introduction 
Verapamil hydrochloride, belonging to phenylalkylamine group of calcium channel 
blockers, is chemically 5-[N-(3,4-dimethoxyphenylethyl)methylamino]-2-(3,4-
dimethoxyphenyl)-2-isopropyl valeronitrile hydrochloride [1]. The drug is officially listed in 
British, United States and Indian Pharmacopoeias [2-4] . It is a potent antihypertensive agent 
with significant depressant effects and has been recommended for intravenous therapy of 
supraventricular tachyarrhythmias [5]. 
The drug has been determined in biological fluids and for pharmaceutical dosage forms 
by a variety of analytical techniques such as high performance liquid chromatography [6-11], 
gas liquid chromatography [12], capillary gas chromatography [13], high performance thin 
layer chromatography [14], potentiometry [15] and potentiometry-conductometry [16]. The 
visible spectrophotometric methods are the instrumental methods of choice, which provides 
practical and significant economic advantages over the other methods. In the literature, only 
few spectrophotometric methods have been reported which are usually based on either 
extractable ion-pair complex formation with bromophenol blue, bromocresol purple, 
bromocresol green, bromothymol blue and methyl orange [17]; solochrome black-T, 
solochrome dark blue, solochrome cyanine R and fast sulfone FF [18]; eriogloucine and 
indigocarmine [19]; alizarin red-S [20] or charge transfer complex formation with 
polyhalo/polycyanoquinones [21-22] and azo dyes [23]. However, some of these methods 
suffer from one or other disadvantages such as low sensitivity, lack of selectivity and simplicity. 
Chloramine-T is a strong oxidant in both acidic and alkaline media {Ered= 1.138 at pH 
0.65 and 0.5 at pH 12) [24-25]. In acidic aqueous solution, chloramine-T is thought to exist 
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in a complex series of equilibria [26] which indicates that the probable oxidising species in 
acidified chloramine-T is hypochlorous acid. 
Chloramine-T was initially introduced as a disinfectant and antiseptic but nowadays 
widely used as an oxidant for various organic functional groups [27]. It has been used as a 
reagent for the spectrophotometric determination of p-aminobenzenesulphonamides [28] and 
sulphamethoxazole, tetracycline hydrochloride, amidopyrine, nifurtimox and isoniazid [29], 
which involves the addition of excess chloramine-T and the determination of unreacted 
reagent. Chloramine-T is also utilised in the titrimetric determination where the end point is 
detected with either a visual indicator [28, 30-32] or potentiometrically [31 ] . 
This chapter describes the spectrophotometric determination of verapamil 
hydrochloride based on its oxidation with chloramine-T in acidic medium producing a yellow 
chromophore. 
Experimental 
Apparatus 
Spectronic 20D+ spectrophotometer (Milton Roy, USA) with matched glass cuvettes 
was used for spectral runs and absorbance measurements. 
Reagents 
A 0.4% verapamil hydrochloride (Sigma, USA) solution was prepared in AR-grade 
methanol (S.D. Fine Chem. Ltd., India) and was further diluted according to the need. 1% 
solution of chloramine-T (E. Merck, India) and 5 M hydrochloric acid (E. Merck) were prepared 
in doubly distilled water. 
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Recommended procedure 
Into a series of 10 mL volumetric flasks 1 mL of varying concentrations of verapamil 
hydrochloride, upto 340 \xg mL \ were pipetted out. To each flask 2.5 mL of 1% chloramine-T 
solution and 6 mL of 5 M HCI were added and diluted to the mark with doubly distilled water. 
The content was mixed well and kept at room temperature for 15 minutes. The absorbances 
were measured at 425 nm against the reagent blank prepared simultaneously omitting the 
drug. The amount of drug in each sample were calculated either from the calibration graph or 
regression equation. 
Analysis of verapamil iiydrocliloride in pharmaceutical formulations 
Ten tablets of verapamil hydrochloride, equivalent to 400 mg of pure drug, were 
grounded to fine powder. The whole mass was stirred in methanol and filtered through 
whatmann no. 42 filter paper into a 100 mL volumetric flask. The residue was washed well with 
methanol. The filtrate and washings were diluted to 100 mL volume. This solution was diluted 
according to the need and analysed by the recommended procedure. 
Results and discussion 
Chloramine-T is well known oxidant and its oxidative behaviour resembles to that of 
the hypohalites. Bishop and Jennings [33], Morris et. a/. [34] and Higuchi and Hussain [35] 
have studied the equilibria involved in acidified chloramine-T solution and suggested the 
formation of hypochlorous acid. This reacts with verapamil hydrochloride to form the relevant 
oxidation products. It is also known that N-bromosuccinimide reacts with tertiary amine [36]. 
In such studies, a methyl or methylene group attached to nitrogen was required and >N-CH2 
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linkage was cleaved preferentially giving yellow coloured products. In a similar fashion it is 
believed that verapamil is oxidised by hypochlorous acid in which >N-CH2 bond is cleaved 
resulting in the formation of aldehyde and secondary amine. The oxidation product absorbs 
maximally at 425 nm (Fig. 3.1). Therefore, based on the literature background and our 
findings, the reaction mechanism was proposed and given in Scheme 3.1. 
The optimum conditions for the assay of verapamil hydrochloride were established via 
a number of preliminary experiments. 
Effect of time 
To investigate the effect of time on the colour development, 1 mL of 0.2% verapamil 
hydrochloride was pipetted in a 10 mL volumetric flask, 2.5 mL of 1 % chloramine-T and 6 mL 
of 5 M HCI were added and diluted to the mark with doubly distilled water. The absorbance was 
recorded as a function of time. The results showed (Fig. 3.2) that the absorbance became 
constant after 13 minutes and remained unchanged upto 20 minutes. Thus absorbance was 
measured within the stability period. 
Effect of chloramine-T concentration 
To 1 mL of 0.2% verapamil hydrochloride, varying volumes (0.5 - 3.0 mL) of 1% 
chloramine-T and 6 mL of 5 M HCI were added. The coloured product was diluted to 10 mL 
with doubly distilled water and absorbances were measured against the corresponding reagent 
blanks after 15 minutes. The results (Fig. 3.3) showed that the highest absorbance was 
obtained with 2.25 mL, which remained constant with higher amounts of chloramine-T. Thus, 
2.5 mL of 1% chloramin^Twas added for colour development. 
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467 
Wavelength (nm) 
Fig. 3.1 . Absorption spectra of the oxidation product of verapamil (•) 
and its reagent blank(o). 
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(1) Formation of hypochlorous acid 
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(2) Oxidation of verapamil by hypochlorous acid 
H3CO 
\ / 
CH3 CH(CH3)2 
-CH2CH2NCH2CH2CH2C CN 
H3CO 
OCH^ 
OCH3 
H" 
H3CO-
\ / 
H3CO 
^ C H a 
CH2CH2N + 
H 
H, 
+ HOCI 
J" 
CH(CH3)2 
C CH2CH2C CN 
Scheme 3.1 
OCH3 
OCHq 
85 
0.8 - , 
0 . 7 -
0 . 6 -
0) 
(d 
.a 
o 
.o 
< 0.5 
0.4-
0.3 
"T" 
16 -r 21 
"T" 
26 
T " 
31 36 
Time (min.) 
Fig. 3.2. Effect of time on the oxidation of verapamil hydrochloride. 
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Fig. 3.3. Effect of volume of 1% chloramine-T on the oxidation 
of verapamil hydrocfiloride. 
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Effect of the concentration of hydrochloric acid 
To study the effect of the concentration of hydrochloric acid, the reaction was carried 
out in a series of 10 mL volumetric flasks containing 200 |xg mL"^  verapamil hydrochloride, 2.5 
mL of 1% chloramine-Tand varying volumes of 5 M HCI (2.0 - 6.5 mL). It is apparent from the 
Rg. 3.4 that the maximum absorbance was found with 5.8 mL of 5 M HCI, beyond which the 
absorbance became constant. Thus, 6 mL of 5 M HCI was used throughout the experiment. 
Analytical data 
Under the optimum experimental conditions, main merits of the procedure for the 
determination of verapamil hydrochloride have been established by least square treatment of 
the results. The absorbance responses at 425 nm were found to be linear in relation to the 
concentration of verapamil hydrochloride upto 340 fig mL"' (Fig. 3.5) with a molar absorptivity 
of 2 X i o n moh^ cm-^ Regression analysis of Beer's law plot was made to evaluate intercept, 
slope and correlation coefficient {rj and the values were found to be 0.29 xlO ^ 4.05 xlO"^ 
and 0.9999, respectively which yielded the regression equation, A -0.29x10-^+ 4.05x10~K 
(where A is the absorbance and C is the concentration of verapamil hydrochloride in ^g mL"^). 
The detection limit for the proposed method was 0.97 ^g mL-^ computed from the following 
equation [37]. 
Detection limit = / SQ 
n — 1 
where 5 / = variance, n = number of samples, t= Student's /'-^/alue at 95% confidence level 
and d = slope of the line of regression. The high value of correlation coefficient and small value 
of intercept on the ordinate, which was close to zero, validated the linearity of calibration 
curve 
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Fig. 3.4. Influence of the volume of 5 M hydrochloric acid on the oxidation 
of verapamil hydrochloride. 
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Fig. 3.5. Calibration curve for tiie determination of verapamil hydrociiloride. 
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whereas detection limit and slope indicated the good sensitivity of the method. Also, the small 
degree of scattering of the experimental data points around the line of regression was 
confirmed by the small value of variance, i.e. 5.33 xlQ-^. 
There is also strong correlation between slope and intercept, which has been 
established by the 95% joint confidence region drawn for them [38]. It is evident from the Fig. 
3.6 that the joint confidence region is bounded by an ellipse having the point of best fit as its 
centre. It can also be seen that the points with an intercept of zero fell well within the ellipse 
and thus, confirmed that there is no significant deviation from the zero. 
Regression analysis of the calibration data also makes it possible to evaluate the error, 
Sc, in the determination of a given concentration of verapamil hydrochloride [39]. Fig. 3.7 
shows the graph of Sc against the concentration of verapamil hydrochloride. The error is 
minimum when the actual absorbance become equal to the average absorbance value in the 
calibration graph which corresponds to 125 |ig m l " ' . This statistical treatment may be used to 
establish the confidence limit at the selected level of confidence (Fig 3.8) for the determination 
of unknown concentration by using the equation [40]. 
tpSo 
c. + 
~ \2 1 (y - y) 1 + + 
b^(L'C^- nC^) 
1/2 
C,±AC 
In order to test the precision and accuracy of the proposed method ten successive 
determinations of 200 |ug m b ' of verapamil hydrochloride were carried out. The percent 
relative standard deviation (%RSD) and error (%Er) were found to be 0.24 and 0.22 respectively. 
The results, therefore, indicated that the method has safeiartory precision and accuracy. The 
commonly encountered execipients in the pharmaceutical dosage forms did not interfere. 
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Fig. 3.6. Plot of joint confidence region (at P = 0.05) for the slope and intercept 
of the line of regression for the determination of verapamil hydrochloride. 
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Fig. 3.7. Error (SC)\K\ the determination of the concentration of verapamil hydrochloride. 
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Fig. 3.8. Variation in the confidence limit at 95% confidence level for the 
determination of verapamil hydrochloride. 
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As an additional demonstration of accuracy, recovery experiments were carried out by 
adding a fixed amount of verapamil hydrochloride to a preanalysed tablet. The results are 
shown in Table 3.1. It is apparent from the table that results were reproducible with low percent 
relative standard deviations (0.3 - 0.82) and mean recoveries were in the range of 99.4 -
100.3%. 
The method was successfully applied to the determination of verapamil hydrochloride 
in tablets available locally. Satisfactory results (Table 3.2) were obtained for the recovery of 
drug and were in good agreement with the label claimed. The results of the proposed method 
were statistically compared with those obtained by the reference method [22]. The calculated 
Student's t- and f-values were less than the theoretical ones at 95% confidence level. The 
statistical evaluation indicated that there was no significant difference between the methods 
compared. 
The proposed method is advantageous when compared to other existing visible 
spectrophotometric methods in wider linear range of estimation with lower value of percent 
relative standard deviations (Table 3.3). This is a decisive advantage since commercial dosage 
forms contain higher amounts. The method is sensitive enough to permit the determination of 
as little as 0.97 fig mL ' of the drug. The proposed method, therefore, is simple, sensitive and 
reproducible and can be applied for the routine analysis of verapamil hydrochloride in the 
quality control laboratories. 
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Table 3.1. Determination of verapamil hydrochloride in dosage forms by standard addition 
method. 
Pharmaceutical Amount taken Amount added Total amount Recovery RSD 
preparations (^g mL~i) (ng mL-i) found (|ag mL-i)» /^ ja i%u 
Calaptin-40 
lsoptin-40 
Vasopten-40 
25 
150 
25 
150 
25 
150 
25 
150 
25 
150 
25 
150 
49.85 
300.20 
50.15 
300.94 
49.10 
300.2 
99.71 
100.10 
100.30 
100.30 
99.40 
100.10 
0.73 
0.30 
0.82 
0.45 
0.75 
0.67 
' Five independent analyses. 
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Table 3.2. Analysis of pharmaceutical preparations by the proposed and reference methods. 
Pharmaceutical Labelled Proposed method Reference method [22] ?M/C*' Fcai^ 
Preparations Amount Recovery RSD Recovery RSD 
(mg) {%Y {%Y [%Y {%Y 
Calaptin 40 99.76 0.49 99.65 0.67 0.3154 1.9 
Isoptin 40 100.12 0.41 99.88 0.49 0.8253 1.42 
Vasopten 40 99.63 0.38 99.88 0.77 0.6720 4.16 
^ Average of five independent analyses. 
''Theoretical /-and f-values at 95% confidence level are 1.86 and 6.39 respectively [41]. 
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Table 3.3. Comparison of the proposed method with other spectrophotometric methods for 
the determination of verapamil hydrochloride in pharmaceutical formulations. 
Reagent 
Eriogloucine^ 
Indigocaramine^ 
Bromocresol purple^ 
Chromotrope 2B 
Chromotrope 2R 
Solochrome dark blue^ 
Solochrome cyanine R^  
Chloramine-T 
/-max 
(nm) 
627 
602 
420 
530 
546 
528 
445 
425 
Beer's law limit 
(ng mL-1) 
1.3-5.3 
33-130 
4 - 2 4 
5-59 
5-59 
10-38 
8 -30 
0-340 
RSD (%) 
1.45 
1.53 
-
-
-
1.53 
1.24 
0.3-0.82 
References 
[19] 
[19] 
[17] 
[23] 
[23] 
[18] 
[18] 
This work 
'Extractive method. 
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Introduction 
Amiodipine besylate is listed in Martindale, The Extra Pharmacopoeia and European 
Pharmacopoeia [1 -2 ] which is chemically (4R,S)-3-ethyl 5-methyl 2-(2-amino-ethoxy-
methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methylpyridine-3,5-dicarboxylate monobenzene 
sulphonate, is approved for the treatment of variant and stable angina and hypertension. It is 
relatively a new long acting calcium channel blocker with slow onset of vasodialatory action [ 3 -
4]. It may also be used for dilated cardiomyopathy and exhibits ameliorating effects on plasma 
and myocardial catecholamines with a significant reduction of calcium deposition [5 -6 ] . In 
addition to calcium channel blocking ability, amiodipine also inhibits vascular smooth muscle 
cell growth through interactions with targets other than L-type calcium channels [7]. 
Amiodipine is more selective for arterial vascular smooth muscle than cardiac tissues. Due to 
these important pharmacological responses, development of sensitive and accurate methods 
for the determination of amiodipine besylate is desired. 
Different methods for the quantification of amiodipine besylate have been reported 
which include high performance liquid chromatography [8-13] , reversed phase high 
performance liquid chromatography [2,14-16], high performance thin layer chromatography 
[17-20], gas chromatography [21], gas chromatography-mass spectrometry [22], liquid 
chromatography with tandem mass spectrometry [23] and fluorimetry [24]. Though these 
methods are sensitive enough but are expensive and not easily manageable. On the other 
hand, spectrophotometry is still the technique of choice since it is sensitive, economical, rapid 
and more easily manageable for the third world countries. 
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Few spectrophotometric methods have been reported for the assay of amiodipine 
besylate based on extractable ion-pair complexes [25-29], oxidative coupling with 3-methyl 
2-benzothiazolinone hydrazone hydrochloride [30], with sodium hydroxide [31], derivative 
spectroscopy [32-33], simultaneous multicomponent mode of analysis [34] and charge 
transfer complexation with p-chloranilic acid [35] and chloranil [36]. It has also been 
determined based on the reaction of-NHz group with ninhydrin in drug formulations [37]. 
A literature survey of charge transfer complexation reactions of polyhalo/ 
polycyanoquinones with basic nitrogenous centres reveals that 2,3-dichloro 5,6-dicyano 1,4-
benzoquionone (DDQ) is one of the sensitive reagents among them which acts as an electron 
acceptor and yields more sensitive results in comparison to other polyhaloquinones [38-41] . 
In 1964, Jaroslav Bartos introduced ascorbic acid as a sensitive and economical 
reagent for the detection and determination of primary amino group in N, N-dimethyformamide 
(DMF) medium [42]. Since then the mechanism of this reaction has not been exactly elucidated 
yet, so no much attention have been paid to the use of ascorbic acid as an economical 
spectrophotometric reagent for the determination of amino group specially in pharmaceutical 
analysis. 
This chapter describes two sensitive, fast, simple and economical methods for the 
determination of amiodipine besylate in pure and dosage forms. The first method is based on 
the charge transfer complexation reaction of amiodipine with DDQ. The second procedure 
utilises the reaction of primary -NH2 group of the drug with ascorbic acid in DMF medium. The 
proposed methods are validated statistically. 
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Experimental 
Reagents and materials 
All chemicals used were of AR-grade. Water was doubly distilled. A 0 .1% solution of 
amiodipine besylate (Wockhardt Ltd., India) was prepared in chloroform. 0 .1% solution of 
amiodipine besylate was also prepared in N, N-dlmethylformamide (S.D. Fine Chem. Ltd., 
India). As reagents 0.05% DDQ (Fluka, Switzerland) solution in acetonitrile and 0.5 M aqueous 
sodium carbonate (E. Merck, India) solution were prepared for DDQ method. For the second 
method, 0.2% ascorbic acid was prepared by dissolving 100 mg of ascorbic acid (S.D. Fine) in 
0.5 mL of water in a 50 mL standard flask and diluting to the volume with DMF. 
Recommended Procedures 
DDQ Method 
Preparation of amiodipine base solution 
In a 150 mL separatory funnel, 50 mL of 0 .1% amiodipine besylate solution in 
chloroform was transferred followed by 75 mL of 0.5 M aqueous sodium carbonate solution. 
The content was mixed well and shaken for few minutes. The organic layer was separated and 
dried over anhydrous sodium sulphate. A 25 mL portion of organic layer containing amiodipine 
base was evaporated to dryness and the residue was taken up with acetonitrile and transferred 
to 50 mL standard volumetric flask, diluting to volume. This corresponds to 0.05% amiodipine 
base solution. 
Procedure for the determination 
Aliquots of 0.05% amiodipine base corresponding to 1 - 125 |ig mL^ were 
transferred into a series of 5 mL volumetric flasks. 1.0 mL of 0.05% DDQ solution was added 
10^ 
in each flask and diluted to volume with acetonitrile. The coloured product formed immediately 
and remained stable from 3 - 2 5 minutes. Therefore, the absorbances were measured within 
the stability period at 580 nm against the reagent blank prepared simultaneously. 
Ascorbic Acid Method 
Into a series of boiling tubes, aliquots of 0 .1% amiodipine besylate solution in DMF (10 
- 140 |ig mL-i) were pipetted. To each tube, 2.5 mL of 0.2% ascorbic acid solution was 
added. The total volume in each tube was maintained to 5 mL by adding DMF. The contents 
were mixed well and placed on a water bath maintained at 100±1 °C for 25 minutes. The 
solutions were cooled to room temperature. The reaction mixture and their corresponding 
washings were transferred and collected into a series of 10 mL volumetric flasks. They were 
diluted to volume with DMF. The absorbances were measured within the stability period of 4 
hours at 530 nm against the reagent blank prepared simultaneously omitting the drug. 
Analysis of Pharmaceutical Formulations 
Ten tablets (claiming for 10 mg of amiodipine besylate per tablet) were finely 
powdered and extracted into sufficient volume of chloroform with shaking. The residue was 
filtered on whatmann filter paper no. 42 and the filtrate was diluted to 100 mL with chloroform. 
The solution of amiodipine base was prepared as discussed above and the drug was analysed 
following the recommended procedure using DDQ solution as the reagent. 
An accurately weighed portion of powdered tablets equivalent to 100 mg of amiodipine 
besylate was stirred with sufficient volume of DMF and left standing for 10 minutes. The residue 
was filtered on whatmann filter paper no. 42 and washed well with DMF. The filtrate and 
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washings were diluted to volume into a 100 mL volumetric flask. The assay was completed 
following the recommended procedure using ascorbic acid solution as the reagent. 
Results and discussion 
Reaction mechanism and IR studies 
The molecular interactions between electron donors and acceptors are generally 
associated with the formation of intensely coloured charge transfer complexes or radical anions 
depending on the polarity of the solvent used. DDQ is a u-acceptor which readily forms charge 
transfer complexes with basic nitrogenous compounds as n-donors [38-41], Some salts of 
amines do not react with a- or n- acceptors because of non-availability of lone pair of 
electrons. In a similar manner, amiodipine besylate does not react with DDQ. In order to 
determine amiodipine besylate, the drug was dissolved in chloroform and shaken with a 0.5M 
aqueous sodium carbonate solution. This treatment yielded amiodipine base in chloroform layer 
and evaporated to dryness. The residue was taken up in acetonitrile, a more polar solvent. The 
amiodipine base acts as an n-donor to form reddish violet coloured charge transfer complex 
with DDQ showing absorption maxima at 435, 550 and 580 nm (Fig. 4.1). These bands may be 
attributed to the formation of DDQ radical anions, which probably resulted through the 
dissociation of the donor-acceptor complex in a highly polar solvent like acetonitrile. In order 
to avoid the maximum interference from the reagent blank, the absorption band at m^ax 580 
nm was chosen for the analytical studies. The Job's plot (Fig. 4.2) suggested a donor to 
acceptor ratio of 1 : 2, confirming the presence of two n-donating centres in the amiodipine 
'base molecule [47]. On the basis of the literature background and our experimental 
observations, a reaction mechanism is proposed and given in Scheme 4.1. 
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A purple red coloured product is obtained on heating amiodipine besylate with ascorbic 
acid in DMF, which absorbed maximally at 530 nm (Fig. 4.3). On heating in water-bath, the 
oxidation of ascorbic acid occurs mainly due to the formation of dehydroascorbic acid [48]. 
The carbonyl group further reacts with -NH2 group of amiodipine to form a purple red coloured 
imine. The IR spectrum of amiodipine besylate (Fig. 4.4) displayed a band in the region 3120 
- 2950 cm-^  attributed to N^-H stretching mode. A sharp band at 1697 cm ' may be due to 
C=0 stretching vibration. The aromatic nature of the drug is characterized by the bands 
appearing in the region 1610 - 1450 cm-'.The band at 1303 cm"' and other bands in the 
region 1200 - 1000 cm ' may be assigned to C-N (ring) and C-N (aliphatic amine) stretching 
vibrations [49]. The IR spectrum of the reaction product (Fig. 4.5) exhibits a broad band in the 
region 3600 - 3300 cm ' which may be attributed to -OH and -CH stretching vibrations 
wherease N'^-H stretching mode disappeared. Another sharp and strong band at 1670 cm^' 
suggested the formation of C=N group. The C=0 stretching vibration is also shifted to a lower 
value and may appear in the C=N group region. The IR spectrum of the product has also 
indicated the OH deformation vibrations and the presence of C-O-C stretching appearing at 
1256 and 1102 cm ' , respectively. Thus the comparative study of the IR spectra of amiodipine 
besylate and the reaction product suggested an imine formation. The reaction mechanism is 
proposed in Scheme 4.2. 
Optimization of Variables 
In DDQ method, the only effective variable is the concentration of DDQ since the 
reaction gets stabilised within 3 minutes and remains unaffected for further 20 minutes. To 
study the effect of concentration of DDQ, varying volumes of 0.05% reagent were mixed with 
no 
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Fig. 4 .3 . Absorption spectra of the reaction product of amiodipine besylate with ascorbic 
acid in DMF (•) and its reagent blank ( D ) . 
in 
Wavenumber (cm^^) 
Fig. 4.4. FTIR-spectrum of amiodipine besylate. 
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Fig. 4.5. FTIR-spectrum of the reaction product of amlodipine besylate-ascorbic acid. 
I. Formation of dehydroascorbate from ascorbic acid. 
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Scheme 4.2 
lU 
0.5 mL of drug in a 5 mL standard flask and diluted to volume with acetonitrile. The 
absorbances were measured after 3 minutes of mixing at 580 nm against the corresponding 
reagent blanks. It was found that 0.5 mL of the reagent gave the highest absorbance (Fig. 
4.6); above this volume the absorbance remains constant. A volume of 1.0 mL was, therefore, 
used in all further measurements. 
To optimize the heating time for ascorbic acid method, 1.0 mL of 0 .1% amiodipine 
besylate was mixed with 2.5 mL of 0.2% ascorbic acid and heated at 100±1°C. The 
absorbance was measured at 530 nm against the reagent blank as a function of heating time. 
The results (Fig. 4.7) show that the absorbance remains constant between 22 and 32 minutes 
of heating. There is an abrupt change in the absorbance above 32 minutes of heating and 
therefore, 25 minutes of heating time was used throughout the experiment. 
In order to study the effect of volume of reagent on the absorbance, varying volume of 
0.2% ascorbic acid was mixed with 1.0 mL of 0 .1% amiodipine besylate in different boiling 
tubes and the contents were heated on the water bath at 100±1 °C for 25 minutes. The 
highest absorbance was obtained with 1.75 mL of the reagent (Fig. 4.8); above which the 
absorbance remains unaffected. A 2.5 mL of the reagent was taken as the optimum value. 
Analytical Data 
Under the optimum experimental conditions, linear calibration graphs were obtained over 
the concentration ranges 1 - 125 and 10 - 140 |Lig mL-^  (Fig. 4.9 and 4.10) of amiodipine 
besylate with molar absorptivities of 0.60 xlO^ and 0.32 xlO^ L moM cm^' using DDQ and 
ascorbic acid, respectively. The calibratioa data w r e fitted by least square treatment and the 
regression equations obtaindforDDQandascorbicacid m e t h o d s m e / l = i 5 ^ ^ / ^ i ^ ^ ^ ^ ; ^ - . ^ 
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Fig. 4.6. Effect of the volume of 0.05% 2,3-dichloro 5,6-dicyano 
1,4-benzoquinone solution. 
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Fig. 4.7. Effect of the heating time on the reaction of amiodipine with 
ascorbic acid in DMF. 
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Fig. 4.8. Effect of the volume of 0.2% ascorbic acid solution. 
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Fig. 4.9. Calibration curve for the determination of amiodipine besylate 
(DDQ method). 
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Fig. 4 .10. Calibration curve for ttie determination of amiodipine besylate 
(Ascorbic acid method). 
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and A - -1.55x10-^ + 5.71 x10-K, respectively, In each case, the correlation coefficient was 
found to be 0.9999, indicating the good linearity of both the calibration graphs and the 
intercepts are all close to zero. The confidence intervals of intercepts at 95% confidence level 
were calculated (1.45 xlQ-^ and 1.90 xlO"^ for DDQ and ascorbic acid methods, respectively) 
which confirmed that these are not different from zero. Thus the present methods are free from 
constant errors independent of the concentration of amiodipine besylate. There is also strong 
correlation existing between the slope and intercept. In order to judge the reliability of strong 
correlation of these parameters, more rigorous treatment of calibration data was made to draw 
a joint confidence region (Fig. 4.11 & 4.12), following the method of Mandel and Linnig [46], 
The joint confidence region for slope and intercept is a tilt-less ellipse having the point of best 
fit as its centre. It is evident from Fig, 4.11 and 4.12 that the points for which intercept is zero 
fall well within the ellipse. 
The variance was calculated using the equation 5 / =^Aexp-Acalcf /n - 2 [47] and 
found to be 4.44 xlO"^ and 4.50 xlQ-^ for DDQ and ascorbic acid methods, respectively. The 
small values of variance obtained for both the methods indicated negligible scattering of the 
experimental data points from the line of best fit. The values of correlation coefficients were not 
sufficient enough to evaluate the linearity of the calibration graphs. The linearity was evaluated 
by the percent relative standard deviation of the slope [Sbrei %) [48], The values were found 
to be 0.11 and 0.18 for DDQ and ascorbic acid methods, respectively which indicated better 
linearity of the former method. The statistical analysis of the calibration data also allows the 
calculation of error {S,^ in the determination of a given concentration of amiodipine besylate 
and may be helpful to establish the confidence limits at the selected levels o\ confidence in the 
121 
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Figure 4 . 1 1 . Joint confidence region /^ at P - 0.05J for the slope and intercept of the 
line of regression (DDQ method). 
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Figure 4.12. Joint confidence region /^ at P = O.OSJhr the slope and intercept of the 
line of regression (Ascorbic acid method). 
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determination of unknown concentrations. These parameters were evaluated by using the 
//2 
following formula [49]. ^xo =—^ 
b 
, 1 (yo-yf 
1 +— + « b^S(x,-xf 
I 
Where / and x are the average absorbance and concentration values, respectively for n 
standard specimens. Fig. 4.13 and 4.14 shows the graphs of S^o versus concentration of 
amiodipine besylate. The error is minimum when the actual absorbance is equal to the average 
absorbance which corresponds to about 45 and 70 fig mL~^  for DDQ and ascorbic acid 
methods, respectively. The accuracy and precision of the proposed methods were evaluated by 
the repeated analyses at three different concentration levels. The results are summarized in 
Table 4.1. The standard deviations, relative standard deviations and standard analytical errors 
[50] can be considered to be very satisfactory. 
As an additional demonstration of accuracy, recovery experiments were performed by 
adding a known amount of amiodipine besylate to the preanalysed dosage forms. The results 
showed (Table 4.2) that the mean recoveries were in the range of 99.34 - 100.20%. No 
interference from the common execipients was observed. 
The methods were successfully applied to the determination of amiodipine besylate in 
pharmaceutical formulations. The results of the proposed method (DDQ or ascorbic acid) were 
compared with those of the reference method [30]. Table 4.3 shows that the calculated ^-and 
f-values are less than the theoretical ones, confirming accuracy and precision at 95% 
confidence level. Under the experimental conditions described, the linearity and sensitivity were 
the best with the charge transfer complex formation procedure. Both the proposed 
spectrophotometric methods are simple, sensitive and reproducible. Moreover, these 
procedures are likely to be very suitable for the routine analysis of amiodipine besylate in 
dosage forms. 
12^ 
0.28-, 
0 26 52 78 104 130 
Concentration {|ig mL') 
Fig. 4.13. Plot of error in the determination of the concentration of amlodipine besylate 
by DDQ method. 
125 
0.42 n 
C? 
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Fig. 4.14. Plot of error in the determination of the concentration of amiodipine besylate 
by ascorbic acid method. 
126 
Table 4 .1 . Evaluation of the accuracy and precision of the two proposed procedures. 
Proposed Amount taken Amount Found RSD(%)» SAE'' Confidence 
Methods (mg mL-i) (mg mL-i) ± SD» limif^  
"DDQ ?0 10,01 ±0.06 0^4 003 006^ 
60 60.0010.31 0.51 0.14 0.297 
100 100.03 ±0.54 0.54 0.24 0.516 
Ascorbic acid 20 20.00 ± 0.23 ^^ 4^ oTo 0.216 
80 80.03 ±0.46 0.57 0.20 0.434 
100 100.05 ±0.51 0.51 0,23 0.490 
^Mean ± S.D. for five determinations. 
''SAE, standard analytical error. 
•^ Confidence limit at 95% confidence level and 4 degrees of freedom (/= 2.132) [51]. 
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Introduction 
Diltiazem hydrochloride is an important coronary vasodilator, which reduces total 
peripheral vascular resistance and is included in the calcium channel-blocking group of the 
antianginal drugs. It is chemically (+)-5-(p-methoxyphenyl)-l,5-benzothiazepin^(5H)-
one acetate monohydrochloride, and its tablet formulations are listed in the United States, 
British and Indian pharmacopoeias [1-3 ] . The drug is used in the treatment of angina and 
hypertension [4] and also exhibits direct but weak negative ionotropic and chronotropic effects 
[5 -7 ] . Due to its characteristic short half-life (///?) diltiazem requires frequent dosing in 
therapeutic situations. 
The officially listed methods in the pharmacopoeias for the determination of diltiazem 
are based on the high performance liquid chromatography [1,3] and titrimetry [2], Few other 
high performance liquid chromatographic methods have also been proposed in the literature 
[8-14] . Certain other analytical techniques such as gas chromatography [15,16], high 
performance thin layer chromatography [17], capillary electrophoresis [18] and titrimetry [19] 
were also utilised for its quantification. Based on the inherent property of optical rotation in the 
diltiazem molecule, Li and Qui have developed a polarimetric method for its determination 
[20]. In the literature few spectrophotometric methods have also been reported. These 
methods are based on the formation of ferric hydroxamate due to acetate moiety in the 
diltiazem molecule [21,22], oxidation of the drug with Fe(lll) or excess of N-bromosuccinimide 
and the determination of subsequently produced Fe(ll) with 1,10-phenanthroline or 
unconsumed N-bromosuccinimide with metol-sulfanilamide [23], reaction of hydrolysed 
diltiazem hydrochloride with Folin-Ciocalteau reagent [24]. Some other spectrophotometric 
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methods have also been developed which involved the charge transfer reactions [25], 
oxidation in strong sulphuric acid medium [26] and extractable ion-pair complexes of the drug 
[27-30]. 
To the best of our knowledge, no kinetic spectrophotometric method has been 
proposed for the assay of diltiazem hydrochloride. Potassium permanganate is an economical 
and versatile oxidising agent, which has been frequently used in the kinetic spectrophotometric 
determination of pharmaceuticals in different media [31-33]. In this study diltiazem 
hydrochloride undergoes oxidation with potassium permanganate in alkaline medium and the 
change in absorbance was measured as a function of time at 610 nm and 530 nm. The main 
aim of this work was, therefore, to study the kinetic data and evaluate their analytical 
applicability for the assay of drug in pharmaceutical formulations. 
Experimental 
Instrument 
The absorbance was recorded on a Spectronic 20D+ spectrophotometer (Milton Roy, 
USA) with matched glass cuvettes. 
Materials 
All the chemicals used were of analytical reagent grade. Diltiazem hydrochloride was 
obtained from Sigma Chemical Co. (USA) and was used as received. The commercial diltiazem 
hydrochloride tablets were purchased locally. 
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Reagents and solutions 
Stock solution of diltiazem hydrochloride (1 mg mb^) was prepared in doubly distilled 
water and it was further diluted according to the need. Potassium permanganate (2.5 mg mL~i) 
and 1 M sodium hydroxide solutions were also prepared in doubly distilled water. 
General procedure for the determination of diltiazem hydrociiloride 
(1) Formation kinetics method 
1 mL of potassium permanganate (12.66 xlO"^ M) and 1 mL of sodium hydroxide (1 M) 
were pipetted into a series of 10 mL volumetric flasks. Then 1 mL of diltiazem hydrochloride of 
varying concentrations (1 - 7 pg mL"^ ) was added to each flask and diluted to volume with 
doubly distilled water. The content was mixed well and immediately transferred to cuvette. The 
absorbance at 610 nm was measured as a function of time against the reagent blank (Rg. 5.1). 
The intercept and slope from the initial straight line of the absorbance-time curve was 
obtained. The calibration graphs were constructed by plotting log of intercept vs. the log of 
molar concentration of the drug (log C), log of slope vs. log C and absorbance measured at 
610 nm at a fixed time of 14 minutes vs. the concentration of the drug. 
(2) Degradation Idnetics method 
1 mL aliquots of potassium permanganate (5.06 xlO-^), 1 mL of 1 M sodium 
hydrochloride and varying concentrations of diltiazem hydrochloride ( 4 - 1 2 (jg mL '^) were 
transferred into a series of 10 mL volumetric flasks and diluted to the mark with distilled water. 
The decrease in the absorbance at 530 nm was recorded as a function of time against the 
distilled water (Fig. 5.2). The initial rate of reaction [v) was obtained from the 
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Fig. 5.1. Absorbance-time curve for the varying concentrations of diltiazem hydrochloride and 
fixed potassium permanganate concentration (12.66 xlO^^ M). (•) 2.22 xlCh^ (vj; 
(•) 4.43 x1 Q-6 M; (A) 6.65 x10^6 M; (T) 8.87 x1 Q-^  M; ( • ) 11.09 x1 QS M; ( * ) 
13.30x10-6M;(x) 15.52 x10~6M. 
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1.2-, 
Time (min.) 
Fig. 5.2. Absorbance-time curve for the varying concentrations of diltiazem hydrocfiloride 
and fixed concentration of potassium permanganate (5.06 xlO"^ M), (o) 8.87 
xlO^ M; (A) 13.30 xlO^^ M; ( D ) 17.74 xlO-^ M; (o) 22.17 xlO-^ M; (V) 
26.61 x10^6|vi. 
1S7 
slope of the tangent to the absorbance-time curve. The calibration curve was prepared by 
plotting the log of the initial rate of reaction (log v) vs. log C. The amount of drug is computed 
either from the calibration curves or regression equations. 
Analysis of pharmaceutical preparations 
10 tablets of diltiazem hydrochloride (30 mg of diltiazem hydrochloride per tablet) 
were finely powdered and dissolved in water. Diltiazem hydrochloride content was extracted 
into chloroform. The organic layer was passed through the anhydrous sodium sulphate and 
collected with its washings in a beaker, which was evaporated to dryness. The residue was 
dissolved in water and diluted according to the need. The content of diltiazem was determined 
following the recommended procedures. 
Results and discussion 
It is well known that potassium permanganate behaves as a strong oxidant. The 
alkaline potassium permanganate oxidises diltiazem hydrochloride producing green colour 
owing to the formation of manganate ion, which absorbed maximally at 610 nm. The intensity 
of green colour increases with time and hence, this property has been exploited to develop a 
kinetically based method for the determination of diltiazem hydrochloride. It has also been 
observed that the intensity of purple colour (X^ax 530 nm) decreases with time and therefore, 
another method based on the degradation kinetics was also elaborated. In order to come to 
this conclusion, some preliminary experiments were performed to optimise the temperature, 
reagent concentration and alkalinity. 
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Effect of temperature 
The reaction between diltiazem hydrochloride and alkaline potassium permanganate 
proceeds at room temperature with substantial change in the absorbance with time. The initial 
rate of reaction increases with increase in temperature, resulting an increase in the slope of the 
calibration graph. This suggested a higher analytical sensitivity but at the same time a 
significant decrease in the linearity was noticed which might be due to unwanted chemical 
changes. Therefore, all the absorbance measurements were made at room temperature 
throughout the experiment. 
Effect of potassium permanganate concentration 
The effect of 1 mL of varying concentrations of potassium permanganate (1.27 x l O ^ -
13.92 X 10-3 |v|) on the reaction rate at 610 nm was studied by a fixed time method (14 
minutes) and was found to be constant above 11.39 xlQ-^ M (Fig. 5.3). Therefore, 1 mL of 
12.66 X 10-3 M KMn04 solution was used throughout the experiment carried at 610 nm. The 
influence of reagent's concentration on the initial rate of reaction at 530 nm was also 
examined. The initial rate of reaction increases with increasing concentration of potassium 
permanganate and became constant after 4.43 x 10-^ M. So finally 5.06 x 10-^ M KMn04 
solution was taken as the optimum concentration in the degradation kinetics method (Fig. 5.4). 
Effect of sodium hydroxide concentration 
The effect of sodium hydroxide concentration was investigated in the similar manner as 
for KMn04. The results in both, the formation as well as the degradation methods, showthati mL 
aliquot of sodium hydroxide has no effect either on the absorbance or the rates above 0.9 M 
(Fig. 5.5). 
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Fig. 5.3. Effect of 1 mL of varying concentrations of potassium permanganate. 
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Fig. 5.4. Absorbance-time curve for the varying concentrations of potassium permanganate 
and fixed diltiazem hydrochloride concentration (2.22 xlQ-^M). ( D ) 1.27 xlO^^ M; 
(O) 2.53 X10-31^; (A) 3.80 xlO'^ M; (V) 5.06 xlQ-^ M. 
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Stoichiometry and mechanism of the reaction 
In order to establish the molar ratio between potassium permanganate and diltiazem 
hydrochloride, the limiting logarithmic method [34] was employed. For this purpose, two sets 
of experiments were performed; one with constant KMOOA concentration and varying diltiazem 
hydrochloride concentration (Fig. 5.1) and another with constant diltiazem hydrochloride 
concentration and varying KMn04 concentration (Fig. 5.6). The logarithms of absorbances of 
the two sets were plotted against the logarithms of the respective varied concentrations 
(Fig. 5.7). The slope of the two curves gave the number of moles of diltiazem hydrochloride 
and KMn04, respectively, The molar ratio was found to be 1 : 1 for diltiazem 
hydrochloride/potassium permanganate. 
The diltiazem molecule possesses a thioether linkage, which is susceptible to oxidation 
to the corresponding sulphoxide. On the basis of the experimental findings and literature 
background, a tentative reaction mechanism is proposed and given in Scheme 5.1. 
Statistical analysis and analytical applicability 
Under the optimised experimental conditions, calibration graphs were constructed. The 
plots of (i) log intercept vs. log C (Fig. 5.8); (i i) log initial rate of formation of MnOr^ vs. log C 
(Fig. 5.9); (i i!) absorbance (610 nm) measured at a fixed time of 14 minutes vs. 
concentration (Fig. 5.10); and (iv) log rate of degradation of potassium permanganate (530 
nm) vs. log C (Fig. 5.11), showed a linear dynamic range of 1 - 7, 1 - 5, 1 - 7 and 4 - 12 pg 
mL-', respectively. In view of the extremely sensitive nature of the reaction and narrow linear 
dynamic range, rigorous statistical linearity tests were performed with repeated measurements. 
1^3 
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Time (min.) 
Fig. 5.6. Absorbance-time curve for the varying concentrations of potassium permanganate 
and fixed diltiazem hydrochloride concentration (2.22 xlO^^M). (•) 1.27 xlO^^ M; 
( • ) 2.53 X10-3 M; ( A ) 3,79 xlO^^ M; ( T ) 5.05 xlQ-^ M. 
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Fig. 5.8. Calibration curve (formation kinetics metliod): plot of log intercept vs. log molar 
concentration of diltiazem hydrochloride ( ) and 95% confidence band ( ). 
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Fig. 5.9. Calibration curve (formation kinetics method): \)\oX of log initial rate of reaction vs. log 
molar concentration of diltiazem hydrochloride ( — ) and 95% confidence band (....). 
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Fig. 5.10. Calibration curve (formation kinetics method): \>\o\ of absorbance (610 nm) measured 
at a fixed time of 14 minutes vs. concentration of diltiazem hydrocliloride (—) 
and 95% confidence band (....). 
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Fig. 5.11. Calibration curve (degradation kinetics metiiod): plot of log initial rate of degradation 
vs. log molar concentration of diltiazem hydrochloride ( ) and 95% confidence 
band( ). 
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The main figures of merit are presented in Table 5.1 and 5.2. In all the cases, the distributions 
were found to be normal as indicated by the David's test [35, 39] wherease the corresponding 
variances were homoscedastic when Cochran test [36, 39] was applied. The test for outlier 
among the calibration data was performed using Dixon test and Grubb's single and double 
outlier tests [37-39]. The results show that there is no outlier among the set of data used for 
the calibration purpose. The significance of linear regression method was established by the 
comparative study with the quadratic regression method. In all the cases, the residual variance 
of the linear regression was found to be less than that of the quadratic regression (Table 5.2). 
This clearly indicates a significantly better fit by the linear regression. It was again favoured by 
the Mandel test in which the calculated values were found to be less than the critical values. 
Moreover, the correlation coefficient frj has been often used as a crude parameter for linearity 
on the ground that a linear calibration function usually gives a high correlation coefficient and 
thus misleading in the context of testing for linearity. So, in fact, a numerical value of rcan not 
be interpreted in terms of degree of deviation from linearity. Therefore, to assure the goodness 
of fit in the calibration graphs, lack of fit test was performed. The results obtained are 
summarised in Table 5.3. It is evident from the data obtained that the F- value found by the 
ratio of the mean of squares of the lack of fit value to that of the pure error is less than the 
tabulated values; thus indicating that the goodness of fit is maintained in all the sets of the 
calibration data. 
For the evaluation of precision estimates, repeatability and intermediate precision were 
performed at three different concentration levels throughout the calibration range, The results 
obtained are summarised in Table 5.4. In all the cases, intraserial variances were found to be 
less than their corresponding interserial variances, thus it does not require to perform the 
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Table 5.3. Analysis of variance with lack of fit. 
Methods 
log intercept 
Residual 
Lack of fit 
Pure Error 
log rate of formation 
Residual 
Lack of fit 
Pure error 
Fixed time 
(14 minutes) 
Residual 
Lack of fit 
Pure error 
log rate of degradation 
Residual 
Lack of fit 
Pure error 
Sum of squares 
0,0003281 
0.0002071 
0.0001210 
0.0001508 
0.0001070 
0,0000438 
0.0001593 
0.0001003 
0.0000590 
0.0002068 
0.0001186 
0.0000882 
or 
12 
5 
7 
8 
3 
5 
12 
5 
7 
8 
3 
5 
Mean squares 
0,0000273 
0.0000414 
0.0000173 
0.0000189 
0.0000357 
0.0000088 
0.0000133 
0.0000201 
0.0000084 
0.0000259 
0.0000395 
0.0000176 
f-ratio 
2.394 
4.057 
2.393 
2.244 
* Degrees of freedom. 
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variance ratio test. The standard deviation and relative standard deviation were found to be 
satisfactory. 
The accuracy of the proposed procedures was evaluated by the standard addition 
method as well as by the comparative studies of the proposed procedures with a reference 
method [23]. The recoveries, standard deviations and percent relative standard deviations are 
quite satisfactory wherease t- and f-values were found to be less than their theoretical values 
at 95% confidence level (Table 5.5 and 5.6). 
In conclusion, the proposed procedures are economical, fast and suitable for the 
determination of diltiazem hydrochloride in pure form and pharmaceutical formulations. 
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Abstract 
A new simple, sensitive and reproducible spectrophotometric method for the determination of nifedipine in pure and dosage 
forms has been proposed It is based on the reduction of nifedipine with Zn/NH4C1, followed by coupling with A'-methyl-l,4-ben 
zoquinoneimine—the oxidation product of 4-(methylamino)phenol, to give a chromophore which absorbed maximally at 525 nm 
The experimental conditions were optimised and Beer's law was obeyed over the concentration range of 5-175 [ig ml ' The 
99 7 100 5% and 
© 2002 Editions 
molar absorptivity, detection limit, recovery and RSD were found to be 1 9 x 10^  1 mol ' cm"', 1 1 ng ml 
0 3-0 8%, respectively The proposed method was compared favourably with the official B P method 
scientifiques e( medicaies Elsevier SAS A/I rights reserved 
Keywords Nifedipine 4-(Methylamino)phenol, A' Methyl 1,4 benzoquinoneimine. Potassium dichromate, Visible spectrophotometry 
1. Introduction 
Nifedipine, chemically dimethyl-l,4-dihydro-2,6-
dimethyl-4-(2-nitrophenyl) pyridme-3,5-dicarboxylate 
and pharmacologically a selective L-type slow calcium 
channel antagonist [1,2], is official in United States 
Pharmacopeia XXIII and British Pharmacopoeia [3,4] 
It is commonly used as an antihypertensive and potent 
arterial vasodilator in the management of angina and 
various other cardiovascular disorders [5] It is also 
used as a probe drug to assess cytochrome P-450 III A4 
enzyme activity in vivo [6] Nifedipine decreases cyclic 
guanosine monophosphate in hypoxic lungs like 
inhaled nitnc oxide, exhibits dose dependent depressive 
effect and causes some common side effects due to 
excessive vasodilation [7-9] 
Several HPLC [6,10-12], reversed phase HPLC 
[13,14], HPTLC [15], GC [12,16-19] and voltammetric 
[20] methods have been reported for the assay of 
nifedipine and its related compounds in pharmaceuti-
* Corresponding author 
E-mail address chtl7nr@amu up nic in (N Rahman) 
cals A variety of HPLC and GC methods arc now 
widely used for the determination of nifedipine concen-
tration in biological fluids because of their sensitivity 
and specificity These methods have adequate sensitivity 
to assay lower concentrations of the drug and hence use 
of these methods is justified when the sample matrix is 
complex and nifedipine concentration is low as in the 
case with the biological samples However, the sample 
matrix is usually less complex and analyte concentra-
tion levels are high in case of pharmaceutical analysis, 
hence it is required to develop a fast, simple and 
inexpensive method that can be adopted for routine 
analysis Therefore, spectrophotometry is still consi-
dered as a convenient and low cost technique 
Nifedipine was assayed [21] in pharmaceutical formu-
lations based on the reaction with 4-dimethylammoben-
zaldehyde and subsequent determination at 310 nm 
Beer-Lambert's law was obeyed over the concentration 
range 5-60 ng m l " ' Another spectrophotometric 
method has also been Tecommended for its determina-
tion involving''the formation of blue complex with 
Folin-Ciocalteau reagent [22] A kinetic spectrophoto-
metric method was described for its determination in 
0014-827X/02/$ - see front matter © 2002 Editions scientifiques et medicaies Elsevier SAS All riehts reserved 
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dosage forms The method was based on its oxidation 
by potassium permanganate at neutral pH [23] In 
commercial dosage forms, UV-spectrophotometry has 
also been utilised for its estimation [24,25] The quan-
tification of nifedipine in combined dosage forms were 
made using first derivative [12] and second derivative 
[27] spectra of their solutions in methanol and 0 1 N 
HCl, respectively 
This work describes a new method for the determina-
tion of nifedipine in commercial dosage forms The 
method depends on the reduction of nitro group to 
hydioxylamino group which then reacted with A'-
methyl-l,4-benzoquinoneimine to form coloured 
product The reduction of nitro group of nifedipine to 
hydroxylamino derivative was studied with respect to 
heating time and concentration of Zn/NH4C1 The ef 
fects oi reagent s concentration, buffer and time on the 
formation of chromophore were investigated 
2. Experimental 
2 1 Apparatus 
Spectral runs and absorbances were recorded on a 
Spectronic 20D^ spectrophotometer (Milton Roy, 
USA) pH-meter mode! Ll-IOT (Elico, India) was used 
to measure pH 
2 3 Recommended procedure 
Aliquots of 0 05-1 75 ml of reduced nifedipine (1 mg 
ml" ' ) were transferred into a series of 10 ml standard 
volumetric flasks and then 2 5 ml of buffer solution (pH 
2 9), 1 45 ml of 0 2% 4-(methylamino)phenol and 1 2 ml 
of 0 01 M potassium dichromate were added to each 
flask successively The solutions were allowed to stand 
at room temperature for 18 mm and then made up to 
the mark with doubly distilled water The absorbance 
values of the final coloured solutions were measured at 
525 nm against a reagent blank The amount of the 
drug was computed from a Beer-Lambert's plot 
2 4 Anahsis oj phaimacLUtical Joimulations 
Ten tablets of nifedipine (each claiming 10 mg) were 
finely powdered and thoroughly mixed The powdered 
mixture was transferred in a conical flask 20 ml of 
ethanol was added and gently shaken for 2-3 min 
Then 15 ml of 10% ammonium chloride solution and 2 
g of zinc dust were added and heated on a water bath 
for 8 mm After cooling at room temperature, the 
mixture was added with 30 ml of ethanol and filtered 
on Whatman filter paper no 42 in a 100 ml standard 
volumetric flask The residue was washed with enough 
ethanol and finally made up to the mark Nifedipine 
content was detei mined using the recommended 
procedure 
2 2 Matenah and leai^ents 
(i) 0 1% ethanolic solution of reduced nifedipine was 
prepared by heating a mixture of 100 mg pure nifedip-
ine (J B Chemicals and Pharmaceuticals Ltd , India) 
dissolved in 20 ml ethanol, 15 ml of 10% aqueous 
solution of ammonium chloride (Loba Chemie, India) 
and 2 g of zinc dust for 8 min on a water bath at 
100+ 1 °C The content was cooled at room tempera-
ture and diluted by adding 30 ml of ethanol It was 
filtered on Whatman no 42 filter paper and washed 
with ethanol The filtrate and washings were diluted to 
volume in a 100 ml volumetric flask The whole experi-
ment was performed in dark and in amber-coloured 
glasswares This solution was stable at room tempera-
ture for about 4 days 
(ii) A buffer solution was prepared by mixing appro-
priate volumes of 1 M hydrochloric acid (E Merck, 
India) and 1 M sodium acetate trihydrate (Ranbaxy 
Chemicals, India) 
(in) 0 2% aqueous solution of 4-(methylamino)phenol 
(Loba Chemie) was prepared in doubly distilled water 
It was always freshly prepared after every 5 h 
(iv) 0 01 M potassium dichromate (Loba Chemie) 
was prepared by dissolving 0 7355 g in doubly distilled 
water and made up to 250 ml 
3. Investigation of stability 
The stability of nifedipine under the experimental 
conditions was investigated by incubating 120 |ig m l " ' 
in distilled water or ethanol containing common excipi-
ents at 30 °C for 3 h in the absence of all lights At 
regular time interval the concentration of nifedipine 
was determined by the proposed and reference methods 
[23] 
4. Results and discussion 
The nitro compounds undergo reduction by catalytic 
hydrogenation in the presence of metals (Zn, Fe, Sn) 
and other suitable reagents like, HCl, NH4CI, NaOH or 
KOH Under the proposed condition, nifedipine is re-
duced to hydroxylamino derivative by Zn/NH4C1 
The primary aromatic amines react with 4-(methy-
lamino)phenoI and an oxidising agent such as dichro-
mate [28], A^-bromosuccinimide [29], peroxydisulfate 
[30] or lodylbenzoate [31] to form a purple red product 
It IS believed that on oxidation 4-(methylamino)phenol 
produces N-methyl-l,4-benzoquinoneimine The pri-
mary aromatic amines react with Af-methyl-l,4-benzo-
A' Rahman MN Hodu /11 Farmaco 57 (2002) 435-441 AM 
quinoneimine to form chromophore which absorbed 
maximally at 520-530 nm In this study the reaction of 
hydroxylamino derivative of nifedipine with 4-(methy-
lamino)phenol and potassium dichromate may be as-
sumed to proceed in an analogous manner as the 
product absorbed maximally at 525 nm [28] The stoi-
chiometric ratio of hydroxylamino derivative to A'-
methyl-l,4-benzoquinoneimine was determined by Job's 
method [32] and was found to be 2 1 (Fig 1) The 
chromophore formed was found to be positively 
charged at pH 2 9 as it was adsorbed on cation-ex-
change resin beads The possible reaction sequence is 
presented in Scheme 1 
The optimum conditions for reduction of nifedipine 
to hydroxylamino derivative were established via a 
number of preliminary experiments The effect of varia-
bles on the reduction of the drug was studied by taking 
a separate 10 ml aliquot of 0 1% nifedipine solution 
4 1 Effect oj heating time 
The aliquot of nifedipine was mixed with 200 mg of 
zinc dust and 1 5 ml of 10% ammonium chloride solu-
tion and the content was heated on a water bath at 
100 + 1 °C One miUilitre of aliquot of this solution was 
subjected to colour development The results showed 
that the intensity of the colour reached its maximum at 
7 min of heating and remained unchanged even after 10 
min Therefore, a heating time of 8 min was recom-
mended for reduction 
Q2D-
J QK-
< 
Q10-
QO 02 Q6 
mole fraction of drug 
Fig 1 Job's plot for hydroxylamino derivative of nifedipine and 
N methyl 1 4-benzoquinoneimme (each 2 89 x lO"-' M; 
4 2 Effect of zinc dust 
The effect of the amount of zinc dust on the reduc-
tion of 10 mg nifedipine in the presence of 1 5 ml of 
10% ammonium chloride solution was studied It was 
observed that the absorbance of the coloured solution 
increased up to 150 mg of zinc dust and then remained 
constant at higher amounts Hence, 200 mg of zinc dust 
was taken as optimum value for reduction 
4 3 Effect of ammonium chloride solution 
To study the effect of the concentration of ammo 
mum chloride solution on the reduction of nifedipine 
10 ml of 0 1% nifedipine was mixed with 200 mg of zinc 
dust and varying volumes of 10% ammonium chloride 
solution The content was heated on a water bath at 
100+1°C for 8 mm A plot of absorbance versus 
volume of ammonium chloride solution showed that 
the highest absorbance was obtained with 1 25 ml and 
remained constant beyond this volume Therefore, 1 5 
ml of 10% ammonium chloride solution was taken to 
reduce the drug for further studies 
The optimum conditions for the development of the 
proposed method were established by varying the 
parameters one at a time and observing the effects 
produced 
4 4 Effect of buffer solution 
A constant absorbance was observed in the pH range 
2 75 3 1 In this study, therefore, 2 5 ml of pH 2 9 
buffer solution was used throughout the experimental 
investigations 
4 5 Effect oj time 
To 1 ml of 0 1% reduced drug 2 5 ml of buffer 
solution (pH 2 9), 1 45 ml of 0 2% 4-(methy-
lammo)phenol solution and 1 2 ml of 0 01 M potassium 
dichromate were added and kept at room temperature 
(25 °C) for colour development The intensity of the 
colour was reached to maximum after 15 mm and 
remained constant for 1 h The coloured product was 
diluted to 10 ml with distilled water and absorbance 
was measured at 525 nm against a reagent blank after 
18 mm 
4 6 Effect of 4-(methylammo)phenol solution 
1 ml of 0 1% reduced drug, was mixed with 2 5 ml of 
buffer solution (pH 2 9), varying volumes of 0 2% 
4-(methylamino)phenol and 1 2 ml of 0 01 M potassium 
dichromate and the contents were allowed to stand at 
room temperature for 18 mm The results showed that 
a constant absorbance was found in the range of 1 4 -
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(a) Reduction of nifedipine to hvdroxvlamino derivative 
CHi 
HiCOOC COOCH3 ^ " ^ " ^ ^ ' > H3COOC 
NO2 
COOCH3 
NHOH 
(b) Formation of 4-N-methvlbenzoquinoneimine: 
K2Cr207 
NH(CH3) NCH3 
(c) Coupling with hvdroxvlamino derivative of drua:-
HiC 
H3COOC 
1.5 ml. Therefore 1.45 ml of 0.2% 4-(methy-
lamino)phenol was used in all the subsequent works. 
4.7. Effect of potassium dichromate solution 
In order to study the effect of potassium dichromate 
concentration, the reaction was carried out in a series 
of 10 ml volumetric flasks containing 100 |ig m l ^ ' 
reduced drug, 2.5 ml of buffer solution (pH 2.9), 1.45 
ml of 0.2% 4-(methylamino)phenol solution. This was 
followed by different volumes of 0.01 M potassium 
dichromate ranging from 0.3 to 1.5 ml. The results 
indicate that the highest intensity and reproducible 
results are obtained on using 1 ml of 0.01 M potassium 
dichromate. Therefore, 1.2 ml of this reagent was used 
throughout this work. 
4.8. Analytical data 
Under the optimum experimental conditions, a cali-
bration curve was constructed by plotting absorbance 
at 525 nm versus concentration. Beer's law was obeyed 
within a concentration range of 5-175 ng ml^ ' . Re-
gression analysis using the method of least squares was 
N Rahimm MN Hoda/II Farmaa) 57 (2002) 435-441 4V) 
made to evaluate the slope, intercept and correlation 
coefficient The linear regression equation and correla-
tion coefficient are ^ = 1 3 x 10 ' + 5 3 x 1 0 'C (A, 
absorbance at 525 nm, C, concentration in ng ml" ' ) 
and r = 0 9999 which indicates an excellent linearity 
The molar absorptivity, detection limit and variance 
[33], standard deviations of intercept and slope [34] 
were found to be 1 9 x 10' 1 mol ' c m ', 1 1 (xg ml ' 
and 1 2 X 1 0 - ^ 1 9 X 10 - ' and 1 6 X 10 ^ respec-
tively The small value of variance marks the negligible 
scattering of the experimental data points from the line 
of regression 
The error, 5"^ , in the determination of a given concen-
tration of nifedipine was calculated by statistical analy-
sis of calibiation data using the relation [35] 
osw 
1 {A-A'f 
1 -I 1 ^  — 
n b\TC^ nC^) 
0 750-
0 700-
1 ' 1 
0 % 72 108 144 180 
Concent ralion/|.ig ml 
Fig 2 Errors (S^) in the determination of the concentration of 
nifedipine 
ConoauratiocVug ml ' 
Fig 3 Variation of confidence limit at 95% confidence level m the 
torm of percent uncertainty on the concentration 
where C and A' are average concentration and average 
absorbance values, respectively, for n standard solu-
tions Fig 2 shows the graph of S^ against the concen-
tration of nifedipine The value of S^ reached a 
minimum when the actual absorbance was equal to the 
average absorbance in the calibration graph Thus the 
minimum error was found in the determination of 
about 100 \ig m l " ' nifedipine The value of S^ also 
allows us to establish the confidence limits at a selected 
level of significance [35] The results are shown m Fig 
3 in the foim of percent uncertainty on the concentra-
tion at 95'yii confidence level It is apparent from the 
figure that the relative uncertainty on the concentration 
can be calculated directly over the full range of the 
concentration tested and hence, confidence limit can be 
established 
The stability experiment conducted in the presence of 
commonly encountered excipients such as starch, talc 
lactose and magnesium stearate revealed the fact that 
under the conditions no degradation of nifedipine was 
detected The drug and its photodegradation product 
4-(2-nitrosophenyl)-pyridine homologue may undeigo 
reduction with Zn/NH4C1 to yield hydroxylamino 
derivative However, the determination was done under 
a condition where contact with light was completely 
avoided 
The reproducibility of the method was checked by 
ten replicate determinations at the concentration levels 
of 60, 100, 120 and 150 \ig ml ' The percent relative 
standard deviations were found to vary between 0 3 and 
08 
The accuracy of the method was demonstrated by 
recovery experiments which were carried out by adding 
a fixed amount of pure drug to the preanalysed formu-
lations The analytical results obtained from these in-
vestigations are summarised in Table 1 which indicates 
that common additives and excipients did not interfeie 
with the determination The percent relative standard 
deviations can be considered to be very satisfactory 
The proposed method for assay of nifedipine in 
dosage forms was compared favourably with othei 
existing UV-visible spectrophotometric methods 
(Table 2) It is evident from the table that the method 
has advantages of wider linear dynamic range and high 
precision (%RSD = 0 3-0 8 and 0 4-0 7 for pure and 
dosage forms, respectively) 
Some commercial dosage forms were successfully 
analysed by the proposed method and official B P 
method [4] The results (Table 3) were compared statis-
tically by Student's r-test and variance ratio F-test 
which indicates that there is no significant difference 
between the methods compared 
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Table 1 
Spectrophotometnc determination of nifedipine in pharmaceutical formulations by standard addition method 
Preparations Amount taken (\xg ml ') Amount added (ng ml ') Amount found (ng ml ') Recovery (%) RSD (%) 
Adalat Retard-10 
Calcigard-10 
Nicardia Retard-10 
30 
40 
80 
30 
40 
80 
30 
40 
80 
30 
60 
40 
30 
60 
40 
30 
60 
40 
60 1 
99 5 
120 4 
59 5 
99 8 
120 7 
59 5 
100 4 
120 5 
100 1 
99 5 
100 3 
99 2 
99 8 
100 6 
99 2 
100 4 
100 4 
0 8 
06 
05 
1 0 
08 
05 
07 
04 
05 
Table 2 I aoic z 
Comparison of the proposed method with existmg spearophotomelnc methods for assay of nifedipine in pharmaceutical formulations 
Reagents 
Potassium permanganate 
3,4,5-Trimethoxybenzaldehyde 
4-Dimethylaminobezaldehyde 
Extractive U V •' 
Ethanol and phosphate buffer sal 
Derivative U V 
line 
4-N-Methylaminopheno! and dichromale 
^„,x 
530 
365 
310 
237 
340 
400 
525 
(nm) Linear d)naniic range (ng ml ') 
18^t4 
10-70 
5-60 
0-10 
4-12 
5-175 
Recovery (/>) 
99 5 101 3 
100 2 102 9 
97 8 98 5 
97 8 98 9 
99 7-99 9 
98 5-101 3 
99 7-100 5 
RSD( ) 
1 5 
1 5 
1 4 
0 6 
RcferoiKi-s 
[23] 
[26] 
[21] 
[25] 
[24] 
[12] 
This work 
•' Extracted into chloroform and the solvent was evaporated to dryness Finally, the residue was dissolved in distilled water 
Table 3 
Spectrophotometnc determination of nifedipine m pharmaceutical formulations by the proposed method and B P method 
Preparations Nominal composition (mg) Proposed method Reference method F-value^ 
Recovery- (%) RSD' (%) /*> Recovery" (%) RSD" (%) t^ 
Adalat Retard-10 10 
Calcigard 10 10 
Nicardia 10 
Retard-10 
99 9 
100 2 
99 9 
0 6 
07 
0 4 
0 3923 100 1 
0 6675 100 2 
0 520 100 4 
04 
05 
0 5 
1 3975 2 0306 
0 8836 2 216K 
1 9876 I O';*:: 
^ Five independent analyses 
>>/, the value at 95% confidence level is 2 132 [36] 
"^  F, value at 95% confidence level is 6 39 [36] 
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Abstract A new spectroplioionietric method is described 
for the determination of verapamil hydrochloride, based on 
Its oxidation with chloramine-T in hydrochloric acid me-
dium It produces a yellow colored compound with maxi-
mum absorbance at 425 nm Beer's law was obeyed in the 
concentration range 0-340 \ig mL"' with molar absorptiv-
ity 2x10^ L mol-i cm-' and RSD 0 3-0 82% All variables 
were studied to optimize the reaction conditions No inter-
ferences were observed from the common excipients pre-
sent in the formulations The method has been applied suc-
cessfully to the determination of the drug in pharmaceuti-
cal preparations Statistical comparison of the results with 
those from the reference method reveals excellent agree-
ment and confirms that accuracy and precision are not sig-
nificantly different 
Keywords Verapamil hydrochloride Chloramine-T 
Spectrophotometry Phamiaceutical formulations 
Introduction 
Verapamil hydrochloride, belonging to phenylalkylamine 
group of calcium channel blockers, is chemically 5-[/V-(3,4-
dimethoxyphenyl ethyl)methylamino]-2-(3,4 dimethoxy-
phenyl)-2-isopropyl valeronitrile hydrochloride [1] The 
drug IS officially listed in British, United States, and In-
dian Pharmacopeias [2, 3, 4] It is a potent antihyperten-
sive agent with significant depressant effects and has been 
recommended for intravenous therapy of supraventricular 
tachyarythmias [5] 
The drug has been determined in biological fluids and 
in pharmaceutical dosage forms by a variety of analytical 
techniques such as high-performance liquid chromatogra-
phy [6, 7, 8, 9, 10, 11], gas-liquid chromatography [12], 
N Rahman (M) M N Hoda 
Analytical Research Division, Department ot Chemistry 
Aligarh Muslim University, Aligarh 202002 India 
e-mail chtl7nr_amu@rediffmail com 
capillary gas chromatography [13], high-performance thin 
layer chromatography [14], potentiometry [15] and poten-
tiometry-conductometry [16] The visible spectrophoto-
metric methods are the instrumental methods of choice 
and have practical and significant economic advantages 
over the other methods In the literature few spectrophoto-
metric methods have been reported, these are usually based 
either on extractable lon-pair complex formation with bro-
mophenol blue, bromocresol purple, bromocresol green, 
bromothymol blue and methyl orange [17], solochrome 
black-T, solochrome dark blue, solochrome cyanine R and 
fast sulfone FF [18], eriogloucine and indigocarmine [19], 
alizarin red-S [20] or on charge-transfer complex forma-
tion with polyhalo- or polycyanoquinones [21, 22] and azo 
dyes [23] Some of these methods, however, suffer from 
disadvantages such as low sensitivity, lack of selectivity, 
and complexity 
Chloramine-T is a strong oxidant in both acidic and al-
kaline media (E,ed==l 138 at pH 0 65 and 0 5 at pH 12) [24, 
25] In acidic aqueous solution, chloramine-T is thought 
to exist in a complex series of equilibria [26] which indi-
cates that the probable oxidizing species in acidified chlo-
ramine-T is hypochlorous acid 
Chloramine-T was initially introduced as a disinfectant 
and antiseptic but is now widely used as an oxidant for a 
variety of organic functional groups [27] It has been used 
as a reagent for the spectrophotometric determination of 
/7-aminobenzenesuIfonamides [28] and sulfamethoxazole, 
tetracycline hydrochloride, amidopyrine, nifurtimox, and 
isoniazid [29] which involves addition of excess chlo-
ramine-T and determination of unreacted reagent Chlo-
ramine-T is also used in titrimetric determination, the end 
point being detected with either a visual indicator [28, 30, 
31, 32] or potentiometncally [31] 
This work describes the spectrophotometnc determina-
tion of verapamil hydrochloride on the basis of its oxida-
tion with chloramine-T in acidic medium to produce a 
yellow chromophore 
485 
Experimental 
Apparatus 
A Spectronic 20D* spectrophotometer (Milton Roy, USA) with 
matched glass cuvettes was used for spectral runs and absorbance 
measurements 
Reagents 
Verapamil hydrochloride (Sigma USA) solution (0 4%) was pre-
pared in methanol (AR grade, S D Fine Chemicals, India) and was 
further diluted according to the need Solution of chloramine-T 
(E Merck, India 1%) and hydrochloric acid (E Merck, 5 mol L ') 
were prepared in doubly distilled water 
Recommended procedure 
Different concentrations of verapamil hydrochloride, up to 340 ^g 
mL ', were pipetted (1 mL) into 10 mL volumetric flasks Chio 
ramine T solution (1% 2 5 mL) and HCl (*> mol L ', 6 mL) were 
added to each flask and the solutions were diluted to volume with 
doubly distilled water The contents were mixed well and kept 
at room temperature for 15 mm Absorbance was measured at 
425 nm against the reagent blank prepared simultaneously but 
omitting the drug The amount of drug in each sample was calcu-
lated either from the calibration graph or the regression equation 
Analysis of fomiulations 
Ten tablets of verapamil hydrochloride, equivalent to 400 mg of 
pure drug, were ground to fine powder The whole mass was stirred 
in methanol and filtered through Whatman no 42 filter paper into 
a 100-mL volumetric flask TTie residue was washed well with 
methanol The filtrate and washings were diluted to 100 mL Tins 
solution was diluted according to the need and analyzed by the rec-
ommended procedure 
Results and discussion 
Chloramine-T is well known oxidant, its oxidative behav-
ior resembles to that of hypohahtes Bishop and Jennings 
[33], Moms et al [34], and Higuchi and Hussam [35] have 
studied the equihbna involved in acidified chloramme-T 
solution and suggested the formation of hypochlorous acid 
This reacts with verapamil hydrochloride to form the rel-
evant oxidation products It is also known that N-bromo-
succinimide reacts with tertiary amines [36] In such stud-
ies, a methyl or methylene group attached to nitrogen was 
required and >N-CH2 linkage was cleaved preferentially 
giving yellow colored products In a similar fashion it is 
believed that verapamil is oxidized by hypochlorous acid, 
m which the >N-CH2 bond is cleaved, resulting in the for-
mation of aldehyde and secondary amine. The oxidation 
product absorbs maximally at 425 nm (Fig 1) Therefore, 
based on the literature background and our findings, the 
reaction mechanism was proposed and given in Scheme 1 
The optimum conditions for the assay of verapamil hy-
drochloride were established via a number of preliminary 
experiments 
08 
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Fig. 1 Absorption spectra of the oxidation product of verapamil 
hydiochloride (filledunlcs) and reagent blank (tnipis auh \) 
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Fig. 2 Effect of time on the oxidation of verapamil hydrochloride 
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Fig. 4 Effect of the volume of 5 mol L"' HCl on the oxidation of 
verapamil hydrochloride 
To investigate the effect of time on color development, 
1 mL of 0.2% verapamil hydrochloride was pipetted into 
a 10 mL volumetric flask, 2.5 mL of 1% chloramine-T 
and 6 mL of 5 mol L"' HCl were added, and the mixture 
was diluted to volume with doubly distilled water. The ab-
sorbance was recorded as a function of time. The results 
showed (Fig. 2) that absorbance became constant after 
13 min and remained unchanged up to 20 min. Thus ab-
sorbance was measured within the stability period. 
Effect of chloramine-T concentration 
To 1 mL of 0.2% verapamil hydrochloride, different vol-
umes (0.5-3.0 mL) of 1% chloramine-T and 6 mL of 
5 mol L"' HCl were added. The colored product was di-
O C 
ra 
XI 
Vot, of chtoramine-T (mL) 
Fig. 3 Effect of volume of 1% chloramine-T on the oxidation of 
verapamil hydrochloride 
luted to 10 mL with doubly distilled water and absorban-
ces were measured against the corresponding reagent blank 
after 15 min. The results (Fig. 3) showed that the highest 
absorbance was obtained with 2.25 mL and remained con-
stant for larger amounts of chloramine-T. Thus 2.5 mL of 
1 % chloramine-T was added for color development. 
Effect of hydrochloric acid concentration 
To study the effect of hydrochloric acid concentration the 
reaction was performed in a series of 10-mL volumetric 
flasks containing 2(X) |ig mL~' verapamil hydrochloride, 
2.5 mL of 1% chloramine-T, and different volumes of 
5 mol L-' HCl (2.0-6.5 mL). It is apparent from Fig. 4 
that the maximum absorbance was obtained for 5.8 mL of 
5 mol L"' HCl, beyond which the absorbance became 
constant. Thus, 6 mL of 5 mol L~' HCl was used through-
out the experiment. 
Analytical data 
Under the optimum experimental conditions the main 
merits of the procedure for the determination of verapamil 
hydrochloride were established by least squares treatment 
of the results. The absorbance at 425 nm was found to be 
linearly dependent on the concentration of verapamil hy-
drochloride up to 340 ^g mL~' with a molar absorptivity 
of 2x10^ L mol"' cm"'. Regression analysis of Beer's law 
plot was performed to evaluate intercept, slope, and corre-
lation coefficient (r) and the values were found to be 0.29x 
10-3, 4.05x10-3, and 0.9999, respectively which yielded 
the regression equation, A=0.29xlO-3+4.05xl(h3 c (where 
A is the absorbance and C is the concentration of verap-
amil hydrochloride in ^ig mL"'). The detection limit for 
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Fig.5 Plot of joint confidence region (at p=0.05) for the slope and 
intercept of the line of regression for the determination of verap-
amil hydrochloride 
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Fig.6 Error (S )^ in the detennination of (he concentration of ve-
rapamil hydrochloride 
the proposed method was 0.97 )xg mL"', computed by use 
of the equation [37]; 
Detection hmit =, Si 2 t 
1 b ( I ) 
where So^=variance, n=number of samples, t=Student's 
t-value at 95% confidence level and b=slope of line of re-
gression.The high value of correlation coefficient and small 
value of the intercept on the ordinate, which was close to 
zero, validated the linearity of calibration curve whereas 
detection limit and slope indicated the good sensitivity of 
the method. Also, the small amount of scattering of the 
experimental data points around the line of regression was 
confirmed by the small value of variance, i.e. 5.33x10^. 
There was also strong correlation between slope and 
intercept; this was established by the 95% joint confidence 
region drawn for them [38]. It is evident from the Fig.5 
that the joint confidence region is bounded by an ellipse 
with the point of best fit as its center. It can also be seen 
that the points with an intercept of zero fell well within 
the ellipse and thus confirmed there was no significant de-
viation from zero. 
Regression analysis of the calibration data also make it 
possible to evaluate the error, S ,^ in the determination of a 
given concentration of verapamil hydrochloride [39]. Fig-
ure 6 shows the graph of S^  against the concentration of 
verapamil hydrochloride. The error is minimum when the 
actual absorbance is equal to the average absorbance value 
in the calibration graph, which coiresponds to 125 (ig mLr'. 
This statistical treatment can be used to establish the con-
fidence limit, at the selected level of confidence, for deter-
mination of unknown concentrations, by use of the equa-
tion [40]. 
C ± ^ 
^ ' b 
1/2 
1+1+ ^y-y> = C, ± AC (2) 
where y and C £ are average absorbance and concentra-
tion values respectively for n standard specimens. The re-
— I — 
204 272 340 
Concentration (pg mL"') 
Fig.7 Variation in the confidence limit, at ^)5% confidence level, 
for the determination of verapamil hydrcKhloridc 
suits are shown graphically in Fig. 7 in the form of the per-
centage uncertainty in the concentration at the 95% confi-
dence level and used to calculate the relative uncertainty 
in the concentration over the full range of concentration 
tested. It is, therefore, a guide to establish the confidence 
limit. 
To test the precision and accuracy of the proposed 
method ten successive determinations of 200 ^g mL"' ve-
rapamil hydrochloride were performed. The percentage 
relative standard deviation (%RSD) and error (%Er) were 
found to be 0.24 and 0.22 respectively. The results, there-
fore, indicated that the precision and accuracy of the meth-
od were satisfactory. The commonly encountered excip-
ients in the pharmaceutical dosage forms did not interfere. 
As an additional demonstration of accuracy, recovery 
experiments were performed by adding a fixed amount of 
verapamil hydrochloride to a preanalyzed tablet. The re-
sults are shown in Table 1. It is apparent from the table 
that results were reproducible with low relative standard 
deviations (0.3-0.82%) and mean recoveries were in the 
range of 99.4-100.3%. 
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Table 1 Determination of 
verapamil hydrochlonde tn 
dosage forms by the standard 
addition method 
'Five independent analyses 
Table 2 Analysis of pharma 
ceutical preparations by the pro 
posed and reference methods 
"Average from five indepen 
dent analyses 
•TTieoretical t and F values at 
95% confidence level are 1 86 
and 6 39, respectively [41] 
Table 3 Comparison of results 
from the proposed method with 
those from other spectrophoto 
metric methods for the deter 
mination of verapamil hydro 
chloride in pharmaceutical for 
mulations 
•"Extractive method 
Pharmaceutical 
preparation 
Calaptin 40 
Isoptin 40 
Vasopten-40 
Pharmaceutical 
preparation 
Calaptin 
Isoptin 
Vasopten 
Reagent 
Enogloucinc'' 
Indigocaraminc 
Amount taken 
(^g 
25 
150 
25 
150 
25 
150 
Labeled 
amount 
(mg) 
40 
40 
40 
Bromocresol purple' 
Chromotropc 2 
Chromotropc 2 
B 
R 
Solochrome dark blue'' 
Solochrome cya 
Chloramine T 
nine R" 
mL-') 
Amount added Total amount 
(^g mL-') 
25 
150 
25 
150 
25 
150 
Proposed method 
Recovery 
(%)" 
99 76 
100 12 
99 63 
^TTiax 
627 
602 
420 
530 
546 
528 
445 
425 
RSD (%)" 
0 49 
041 
0 38 
(nm) 
found (jig 
49 85 
300 20 
50 15 
300 94 
49 10 
300 2 
mL-')' 
Recovery 
(%)' 
99 71 
100 10 
100 30 
100 30 
99 40 
100 10 
Reference method [22] t^jij'' 
Recovery 
(%)' 
99 65 
99 88 
99 88 
RSD {%Y 
0 67 
0 49 
0 77 
0 3154 
0 8253 
0 6720 
Beer's law limit RSD (%) 
(Hg mL-') 
1 3-5 3 
33-130 
4-24 
5-59 
5-59 
10-38 
8-30 
0-340 
145 
1 53 
-
-
1 53 
1 24 
0 3-0 82 
RSD 
(%)' 
0 73 
0 30 
0 82 
0 45 
0 75 
0 67 
^calc 
19 
1 42 
4 16 
Reference 
[19] 
[19] 
[17] 
[23] 
[23] 
[18] 
[18] 
This work 
The method was successfully applied to the determind-
tion of verapamil hydrochloride in tablets available lo-
cally Satisfactory results (Table 2) were obtained for the 
recovery of drug and were in a good agreement with the 
label claim The results of the proposed method were sta-
tistically compared with those obtained by the reference 
method [22] The calculated Student's t- and F-values 
were less than the theoretical values for 9 5 % confidence 
level Statistical evaluation indicated there was no signifi-
cant difference between the methods compared (Table 3) 
Conclusion 
The proposed method is a direct oxidative method for the 
determination of verapamil hydrochloride in pure and 
dosage forms which does not require elaborate treatment 
of the analyte and tedious extraction of the chromophore 
produced The proposed method is advantageous when 
compared with other visible spectrophotometnc methods 
because the linear range of estimation is wider and the per-
centage relative standard deviation is lower (0 3 0 - 0 82) 
This is a decisive advantage, because commercial dosage 
forms of verapamil hydrochlonde contain larger amounts 
The method is sensitive enough to enable determination 
of as little as 0 97 ^g mL"' of die drug In conclusion, the 
method is simple, sensitive, precise, accurate, economical, 
and appropriate and can be used for the routine analysis of 
verapamil hydrochlonde m quality-control laboratories 
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B Abstract 
14 
15 Two simple and sensitive spectrophotometric methods have been proposed for the determination of amlodipine 
16 besylate either in pure form or in pharmaceutical formulations. The first method is based on the charge transfer 
17 complexation reaction of the drug with 2,3-dichloro 5,6-dicyano 1,4-benzoquinone (DDQ) to give coloured product 
18 having maximum absorbance at 580 nm. The second procedure depends on the measurement of purple red colour 
19 produced by the interaction of drug with ascorbic acid in A'^.A^-dimethylformamide medium (DMF) which absorbed 
20 maximally at 530 nm. Under the optimized experimental conditions. Beer's law was obeyed in the concentration ranges 
21 of 1-125 and 10-140 ng ml~ ' with DDQ and ascorbic acid, respectively. Both the methods were applied successfully 
22 for the analysis of amlodipine besylate in dosage forms. Results of analyses were validated statistically and through 
23 recovery studies. 
24 © 2002 Published by Elsevier Science B.V. 
25 Keywords: Amlodipine besylate; 2,3-Dichloro 5,6-dicyano 1,4-benzoquinone; Ascorbic acid; Spectrophotometry 
27 
28 
29 
30 
31 
32 
33 
26 1. Introduction 
Amlodipine besylate is listed in Martindale, The 
Extra Pharmacopoeia and European Pharmaco-
poeia [1,2] which is chemically (47?,5')-3-ethyl 5-
methyl 2-(2-amino-ethoxy-methyl)-4-(2-chloro-
phenyl)-1,4-dihydro-6-methyl pyridine-3,5-dicar-
boxylate monobenzene sulphonate, approved for 
the treatment of variant and stable angina and 
* Corresponding author 
E-mail address: chtl7nr_amu@yahoo.com (N. Rahman). 
hypertension. It is relatively a new long acting 34 
calcium channel blocker with slow onset of 35 
vasodilatory action [3,4]. It may also be used for 36 
dilated cardiomyopathy and exhibits ameliorating 37 
effects on plasma and myocardial catecholamines 38 
with a significant reduction of calcium deposition 39 
[5,6]. In addition to calcium channel blocking 40 
ability, amlodipine also inhibits vascular smooth 41 
muscle cell growth through interactions with 42 
targets other than L-type calcium channels [7]. 43 
Amlodipine is more selective for arterial vascular 44 
smooth muscle than cardiac tissues. Due to these 45 
important pharmacological responses, develop- 46 
0731-7085/02/$ - see front matter © 2002 Published by Elsevier Science B.V. 
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0.25 
0.00 4 
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0 . 1 ^ 
650 
Wavelength (nm) / Mole fraction of amlodipine besylate (x ,^) 
Fig. 1. Absorption spectra of the reaction products of amlodipine besylate with DDQ (• ) and ascorbic acid (O) and their respective 
reagent blanks. Job's plot for amlodipine-DDQ complex (•). 
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ment of sensitive and accurate methods for the 
detenaination of amlodipine besylate is desired. 
Different methods for the quantification of 
amlodipine besylate have been reported which 
include high performance liquid chromatography 
[8-13], reversed phase high performance liquid 
chromatography [2,14 16], high performance thin 
layer chromatography [17 20], gas chromatogra-
phy [21], gas chromatography-mass spectrometry 
[22], liquid chromatography with tandem mass 
spectrometry [23] and fluorimetry [24]. Though 
these methods are sensitive enough, they are 
expensive and not easily manageable. On the other 
hand, spectrophotometry is still the technique of 
choice since it is sensitive, economical, rapid and 
more easily manageable for third world countries. 
Few spectrophotometric methods have been 
reported for the assay of amlodipine besylate 
based on extractable ion-pair complexes [25 29], 
oxidative coupling with 3-methyl 2-benzothiazoli-
none hydrazone hydrochloride [30], with sodium 
hydroxide [31], derivative spectroscopy [32,33], 68 
simultaneous multicomponent mode of analysis 69 
[34] and charge transfer complexation with p- 70 
chloranilic acid [35] and chloranil [36]. It has also 71 
been determined based on the reaction of -NH2 72 
group with ninhydrin in drug formulations [37], 73. 
A literature survey of charge transfer complexa- 74 
tion reactions of polyhalo/polycyanoquinones with 75 
basic nitrogenous centres reveals that 2,3-dichloro 76 
5,6-dicyano 1,4-benzoquionone (DDQ) is one of 77 
the sensitive reagents among them which acts as an 78 
electron acceptor and yields more sensitive results 79 
in comparison to other polyhaloquinones [38-41]. 80 
In 1964, Jaroslav Bartos introduced ascorbic acid 81 
as a sensitive and economical reagent for the 82 
detection and determination of primary amino 83 
group in TV.A'^-dimethyformamide medium [42]. 84 
Since then the mechanism of this reaction has not 85 
been exactly elucidated yet, so not much attention 86 
has been paid to the use of ascorbic acid as an 87 
economical spectrophotometric reagent for the 88 
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CH2OCH2CH2NH2 H3C . . 3 - II ipCHzOCHjCHjN: 
H 
COOCM^-
Amlodipine 
H 
I CH2OCH2CH2N: 
COOC] :/2H5 H 
donor 
CT Complexation acceptor (DDQ) 
11 ipCHiOCHjCHiNi 
HjCOOC-' lJ ' -COOqf^Hs H 
(DA complex) 
Fast 
Fast dissociation in polar 
solvent (Acetonitrile) 
V •? N=C H3C- k V. ^= 
1 r / i M - r A ^ n HjCOOC-lLiLcOOO^jHs H N 
H3cooc-i^J-coo9f2H5 " ^-^ n ''' H ^ -
Cl -
(D -colourless) 
(X"- red coloured) 
DDQ radical anion-
the measured species 
Scheme 1. 
JA^ 
89 determination of (jeaction wit^) amino group 
90 specially in pharmaceutical analysis. 
91 This paper describes two sensitive, fast, simple 
92 and economical methods for the determination of 
93 amlodipine besylate in pure and dosage forms. The 
94 first method is based on the charge transfer 
complexation reaction of amlodipine with 95 
DDQ. The second procedure utilizes the 96 
reaction of primary -NH2 group of the drug 97 
with ascorbic acid in A^,A^-dimethylformamide 98 
medium. The proposed methods are validated 99 
statistically. 100 
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I - Formation of dehydroascorbate from ascorbic acid (dehydrogenation) 
HO OH 0 0 
O 0 CH-OH I 
CH2-0H 
2H* 
I 
CH2-0H 
II- Imine formation by coupling of amlodipine with dehydroascorbate 
H 
I H3C N CH2OCH2CH2NH2 
0 P 
2H3C C-0-CH2-CH3 
0 
DMF 
H 
•2H2O 
H3C-H2C-O-C C-O-H3C 
^r, V, ^NH2CH2COH2C^ N CH3 
H3C N CH20CH2CH2N>y_^ I 
~CH-OH 
CH2-0H 
Scheme 2. 
101 2. Experimental 
102 2.1. Reagents and materials 
103 All chemicals used were of AR-grade. Water 
104 was doubly distilled. A 0 .1% solution of amlodi-
105 pine besylate (Wockhardt Ltd., India) was pre-
106 pared in chloroform. 0 .1% solution of amlodipine 
107 besylate was also prepared in A'^,Af-dimethylfor-
108 mamide (S.D. Fine Chem. Ltd., India). As re-
109 agents 0.05% D D Q (Fluka, Switzerland) solution 
110 in acetonitrile and 0.5 M aqueous sodium carbon-
Ill ate (E. Merck, India) solution were prepared for 
112 DDQ method. For the second method, 0.2% 
113 ascorbic acid was prepared by dissolving 100 mg 
114 of ascorbic acid (S.D. Fine) in 0.5 ml of water in a 
50 ml standard flask and diluting to the volume 115 
with DMF. 116 
2.2. Recommended procedure 117 
2.2.1. DDQ method 118 
2.2.1.1. Preparation of amlodipine base solution. \n 119 
a 150 ml separatory funnel, 50 ml of 0 .1% 120 
amlodipine besylate solution in chloroform was 121 
transferred followed by 75 ml of 0.5 M aqueous 122 
sodium carbonate solution. The content was 123 
mixed well and shaken for a few minutes. The 124 
organic layer was separated and dried over anhy- 125 
drous sodium sulphate. A 25 ml portion of organic 126 
layer containing amlodipine base was evaporated 127 
to dryness and the residue was taken up with 128 
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Fig 2. Effect of the volume of 0 05% DDQ ( • ) and 0 2% ascorbic acid ( • ) and the heating time (O). 
acetonitrile and transferred to 50 ml standard 
volumetric flask, diluting to volume. This corre-
sponds to 0.05% amlodipine base solution. 
2.2.1.2. Procedure for the determination. Aliquots 
of 0.05% amlodipine base corresponding to 1-125 
Hg m l ~ ' were transferred into a series of 5 ml 
volumetric flasks. 1.0 ml of 0.05% D D Q solution 
was added in each flask and diluted to volume with 
acetonitrile. The coloured product formed imme-
diately and remained stable from 3 to 25 min. 
Therefore, the absorbances were measured within 
the stability period at 580 nm against the reagent 
blank prepared simultaneously. 
2.2.2. Ascorbic acid method 
Into a series of boiling tubes, aliquots of 0 .1% 
amlodipine besylate solution in D M F (10-140 \ig 
m l " ' ) were pipetted. T o each tube, 2.5 ml of 0.2% 
ascorbic acid solution was added. The total 
volume in each tube was maintained to 5 ml by 
adding D M F . The contents were mixed well and 
placed on a water bath maintained at 100+1 °C 
for 25 min. The solutions were cooled to room 
temperature. The reaction mixture and their cor-
responding washings were transferred and col-
lected in a series of 10 ml volumetric flasks. They 
were diluted to volume with D M F . The absor- 154 
bances were measured within the stabihty period 155 
of 4 h at 530 nm against the reagent blank treated 156 
similarly. 157 
2.2.2.1. Analysis of pharmaceutical formulations. 158 
Ten tablets (claiming for 10 mg of amlodipine 159 
besylate per tablet) were finely powdered and 160 
extracted into sufficient volume of chloroform 161 
with shaking. The residue was filtered on what- 162 
mann filter paper no. 42 and the filtrate was 163 
diluted to 100 ml with chloroform. The solution 164 
of amlodipine base was prepared as discussed 165 
above and the drug was analyzed following the 166 
recommended procedure using D D Q as the re- 167 
agent. 168 
An accurately weighed portion of powdered 169 
tablets equivalent to 100 mg of amlodipine besy- 170 
late was stirred with sufficient volume of D M F 171 
and left standing for 10 min. The residue was 172 
filtered on whatmann filter paper no. 42 and 173 
washed well with D M F . The filtrate and washings 174 
were diluted to volume in a 100 ml volumetric 175 
flask. The assay was completed following the 176 
recommended procedure using ascorbic acid as 177 
reagent. jyg 
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179 3. Results and discussion 
180 3.1. Reaction mechanism and IR studies 
181 
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The molecular interactions between electron 
donors and acceptors are generally associated 
with the formation of intensely coloured charge 
transfer complexes or radical anions depending on 
the polarity of the solvent used. DDQ is a n-
acceptor which readily forms charge transfer 
complexes with basic nitrogenous compounds as 
n-donors [38-41]. Some salts of amines do not 
react with a- or 7i-acceptors because of non-
availabihty of lone pair of electrons. In a similar 
manner, amlodipine besylate does not react with 
DDQ. In order to determine amlodipine besylate, 
the drug was dissolved in chloroform and shaken 
with a 0.5 M aqueous sodium carbonate solution. 
This treatment yielded amlodipine base in chloro-
form layer and evaporated to dryness. The residue 
was taken up in acetonitrile, a more polar solvent. 
The amlodipine base acts as an n-donor to form 
reddish violet coloured charge transfer complex 
with DDQ showing absorption maxima at 435, 
550 and 580 nm (Fig. Ifi. These bands may be 
attributed to the formation of DDQ radical 
anions, which probably resulted through the dis-
sociation of the donor-acceptor complex in a 
highly polar solvent like acetonitrile. In order to 
avoid the maximum interference from the reagent 
blank, the absorption band at -^ a^x 580 nm was 
chosen for analytical studies. The Job's plot (Fig. 
l^ suggested a donor to acceptor ratio of 1:2, 
confirming the presence of two n-donating centres 
in the amlodipine base molecule [43]. On the basis 
of the literature background and our experimental 
observations, a reaction mechanism is proposed 
and given in Scheme 1. 
A purple red coloured product is obtained on 
heating amlodipine besylate with ascorbic acid in 
DMF, which absorbed maximally at 530 nm (Fig. 
Ij^. On heating in a water-bath, the oxidation of 
ascorbic acid occurs mainly due to the formation 
of dehydroascorbic acid [44]. The carbonyl group 
further reacts with - N H j group of amlodipine to 
form a purple red coloured imine. The IR spec-
trum of amlodipine besylate displayed a band in 
the region 3120-2950 c m ' attributed to N + - H 
Concentration of amlodipine besylate (jig mL" ) 
Fig. 4. Plot of error in the determination of the concentration 
of amlodipine besylate by DDQ method ( • ) and ascorbic acid 
method (O). 
Stretching mode. A sharp band at 1697 cm " ' may 
be due to C = 0 stretching vibration. The aromatic 
nature of the drug is characterized by the bands 
appearing in the region 1610-1450 cm ' ' .The 
band at 1303 c m " ' and other bands in the region 
1200-1000 c m " ' may be assigned to C-N (ring) 
and C-N (aliphatic amine) stretching vibrations 
[45]. The IR spectrum of the reaction product 
exhibits a broad band in the region 3600-3300 
cm ~' which may be attributed to -OH and -CH 
stretching vibrations whereas N + - H stretching 
mode disappeared. Another sharp and strong 
band at 1670 cm^ ' suggested the formation of 
C=N group. The C = 0 stretching vibration is also 
shifted to a lower value and may appear in the C= 
N group region. The IR spectrum of the product 
has also indicated the OH deformation vibrations 
and the presence of C - O - C stretching appearing 
at 1256 and 1102 c m " ' , respectively. Thus the 
comparative study of the IR spectra of amlodipine 
besylate and the reaction product suggested an 
imine formation. The reaction mechanism is 
proposed in Scheme 2. 
3.2. Optimization of variables 
In DDQ method, the only effective variable is 
the concentration of DDQ since the reaction gets 
stabilized within 3 min and remains unaffected for 
a further 20 min. To study the effect of the 
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Table I 
Evaluation of the accuracy and precision of the two proposed procedures 
Proposed methods Amount taken (mg ml ') Amount found (mg ml ')+S.D.'' RSD (%)" SAE'' Confidence limit' 
10.01+0.06 
60.00+0.31 
100.03 ±0.54 
20.00 ±0.23 
80.03 ±0.46 
100.05+0.51 
" Mean + S.D. for five determinations. 
'^ SAE, standard analytical error. 
'^ Confidence limit at 95% confidence level and four degrees of freedom {( = 2.132) [51]. 
DDQ 
Ascorbi ic acid 
10 
60 
100 
20 
80 
100 
0.64 
0.51 
0.54 
1.14 
0.57 
0.51 
0.03 
0.14 
0.24 
0.10 
0.20 
0.23 
0.061 
0.297 
0.516 
0.216 
0.434 
0.490 
253 
254 
255 
256 
257 
258 
259 
260 
261 
262 
263 
264 
265 
266 
267 
268 
269 
270 
271 
272 
273 
274 
275 
276 
277 
278 
279 
280 
281 
concentration of DDQ, varying volumes of 0.05% 
reagent was mixed with 0.5 ml of drug in a 5 ml 
standard flask and diluted to volume with aceto-
nitrile. The absorbance was measured after 3 min 
of mixing at 580 nm against the reagent blank. It 
was found that 0.5 ml of the reagent gave the 
highest absorbance (Fig. 2); above this volume the 
absorbance remains constant. A volume of 1.0 ml 
was, therefore, used in all further measurements. 
To optimize heating time for ascorbic acid 
method, 1.0 ml of 0.1% amlodipine besylate was 
mixed with 2.5 ml of 0.2% ascorbic acid and 
heated at 100 ±1 °C. The absorbance was mea-
sured at 530 nm against the reagent blank as a 
function of heating time. The results (Fig. 2) show 
that the absorbance remains constant between 22 
and 32 min of heating. There is an abrupt change 
in the absorbance above 32 min of heating and 
therefore, 25 min of heating time was used 
throughout the experiment. 
In order to study the effect of volume of reagent 
on the absorbance, varying volume of 0.2% 
ascorbic acid was mixed with 1.0 ml of 0.1% 
amlodipine besylate in different boiling tubes and 
the contents were heated on the water bath at 100 
±1 °C for 25 min. The highest absorbance was 
obtained with 1.75 ml of the reagent (Fig. 2); 
above which the absorbance remains unaffected. 
2.5 ml of the reagent was taken as optimum value. 
3.3. Analytical data 
Under the optimum experimental conditions, 
hnear cahbration graphs were obtained over the 
concentration ranges 1-125 and 10-140ng ml 
of amlodipine besylate with molar absorptivities of 
0.60 X 10" and 0.32 x lO'' 1 m o l " ' c m " ' using 
DDQ and ascorbic acid, respectively. The calibra-
tion data were fitted by least square treatment and 
the regression equations obtained for DDQ and 
ascorbic acid methods were A = 3 . 5 4 x l 0 ~ ' + 
8 .88x lO" 'C and A = - 1 . 5 5 x 1 0 - ^ 5 . 7 1 x 
10~^C, respectively. In each case, the correlation 
coefficient was found to be 0.9999, indicating the 
good linearity of both the calibration graphs and 
the intercepts are all close to zero. The confidence 
intervals of intercepts at 95% confidence level were 
calculated (1.45 x 10 ^^ and 1.90 x 10 ~ ' for DDQ 
and ascorbic acid methods, respectively) which 
confirmed that these are not different from zero. 
Thus the present methods are free from constant 
errors independent of the concentration of amlo-
dipine besylate. There is also strong correlation 
existing between the slope and intercept. In order 
to judge the reliability of strong correlation of 
these parameters, more rigorous treatment of 
cahbration data was made to draw a joint con-
fidence region (Fig. 3a and b) following the 
method of Mandel and (Tinning [46]. The joint 
confidence region for slopeand intercept is a tilt-
less ellipse having the point of best fit as its centre. 
It is evident from Fig. 3a and b that the points for 
which intercept is zero fall well within the ellipse. 
The variance was calculated using the equation 
Sl = l.{A^^p-A^^x^fln-2 [47] and found to be 
4.44 x 10 S n d 4.50 x 10"^ for DDQ and ascor-
bic acid methods, respectively. The small values of 
variance obtained for both the methods indicated 
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negligible scattering of the experimental data 319 
points from the line of best fit. The values of 320 
correlation coefficients were not sufficient enough 321 
to evaluate the linearity of the calibration graphs. 322 
The linearity was evaluated by the percent relative 323 
standard deviation of the slope ^ s C i % ^ [48]. The 324^' 
values were found to bs 0.11 and 0.18 for DDQ 325 
and ascorbic acid methods, respectively, which 326 
indicated better linearity of the former method. 327 
The statistical analysis of the calibration data 328 
also allows the calculation of error (5^o) in *he 329 
determination of a given concentration of amlodi- 330 
pine besylate and may be helpful to establish the 331 
confidence limits at the selected levels of confi- 332 
dence in the determination of unknown concen- 333 
trations. These parameters were evaluated by 334 
using the following formula [49]. 335 
- ^ 
III 
(S'fcy, 
(1) .336 
where y and x are the average absorbance and 
concentration values, respectively for n standard 337 
specimens. Fig. 4 shows the graphs of 5vo versus 338 
concentration of amlodipine besylate. The error is 339 
minimum when the actual absorbance is equal to 340 
the average absorbance, which corresponds to 341 
about 45 and 70 {ig ml""' for DDQ and ascorbic 342 
acid methods, respectively. The accuracy and 343 
precision of the proposed methods were evaluated 344 
by the repeated analyses at three different con- 345 
centration levels. The results are summarized in 346 
Table 1. The standard deviations, relative standard 347 
deviations and standard analytical errors [50] can 348 
be considered to be very satisfactory. 349 
As an additional demonstration of accuracy, 350 
recovery experiments vvere performed by adding a 351 
known amount o*" amlodipine besylate to the 352 
preanalyzed dosage forms. The results showed 353 
(Table 2) that the mean recoveries were in the 354 
range of 99.34-100.20%. No interference from the 355 
common excipients was observed. 356 
The methods were successfully applied to the 357 
determination of amlodipine besylate in pharma- 358 
ceutical formulations. The results of the proposed 359 
method (DDQ or ascorbic acid) were compared 360 
with those of the reference method [30]. Table 3 361 
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shows that the calculated t- and f-values are less 
than the theoretical ones, confirming accuracy and 
precision at 95% confidence level 
Under the experimental conditions described, 
the linearity and sensitivity were the best with the 
charge transfer complex formation procedure 
Both the proposed spectrophotometric methods 
are simple, sensitive and reproducible Moreover, 
these procedures are likely to be very suitable for 
the routine analysis of amlodipine besylate in 
dosage forms 
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